WO2008018133A1 - Moisturizing agent, cell-activating agent, skin-whitening agent, agent for suppressing triglyceride accumulation, antioxidant and external preparation for skin - Google Patents
Moisturizing agent, cell-activating agent, skin-whitening agent, agent for suppressing triglyceride accumulation, antioxidant and external preparation for skin Download PDFInfo
- Publication number
- WO2008018133A1 WO2008018133A1 PCT/JP2006/315808 JP2006315808W WO2008018133A1 WO 2008018133 A1 WO2008018133 A1 WO 2008018133A1 JP 2006315808 W JP2006315808 W JP 2006315808W WO 2008018133 A1 WO2008018133 A1 WO 2008018133A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- agent
- extract
- plant
- plant extract
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 49
- 238000009825 accumulation Methods 0.000 title claims abstract description 23
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 19
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 15
- 230000003078 antioxidant effect Effects 0.000 title abstract description 14
- 230000003020 moisturizing effect Effects 0.000 title abstract description 14
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 title abstract description 3
- 239000007854 depigmenting agent Substances 0.000 title abstract 2
- 239000000284 extract Substances 0.000 claims abstract description 49
- 241000196324 Embryophyta Species 0.000 claims abstract description 39
- 239000004480 active ingredient Substances 0.000 claims abstract description 17
- 241000196128 Osmundaceae Species 0.000 claims abstract description 8
- 230000007935 neutral effect Effects 0.000 claims description 21
- 230000002087 whitening effect Effects 0.000 claims description 17
- 239000012190 activator Substances 0.000 claims description 11
- 239000003112 inhibitor Substances 0.000 claims description 11
- 239000004909 Moisturizer Substances 0.000 claims description 8
- 230000001333 moisturizer Effects 0.000 claims description 8
- 230000000699 topical effect Effects 0.000 claims description 5
- 235000015277 pork Nutrition 0.000 claims 1
- 239000000419 plant extract Substances 0.000 description 54
- 210000003491 skin Anatomy 0.000 description 46
- 230000000694 effects Effects 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 239000002609 medium Substances 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 24
- 238000011156 evaluation Methods 0.000 description 24
- 239000000523 sample Substances 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 239000000203 mixture Substances 0.000 description 21
- 235000019197 fats Nutrition 0.000 description 20
- 238000000605 extraction Methods 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 17
- 239000012071 phase Substances 0.000 description 17
- 230000020411 cell activation Effects 0.000 description 16
- 239000003921 oil Substances 0.000 description 15
- 238000002835 absorbance Methods 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 235000019198 oils Nutrition 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 239000008213 purified water Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 241000237502 Ostreidae Species 0.000 description 12
- 235000020636 oyster Nutrition 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 11
- -1 ethylene, propylene, ethanol Chemical class 0.000 description 11
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 10
- 239000003205 fragrance Substances 0.000 description 10
- 238000001816 cooling Methods 0.000 description 9
- 238000004945 emulsification Methods 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 230000002500 effect on skin Effects 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 241001137223 Crenichthys Species 0.000 description 6
- 241000196127 Osmunda Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 230000008099 melanin synthesis Effects 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 230000036548 skin texture Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229940058015 1,3-butylene glycol Drugs 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 230000002292 Radical scavenging effect Effects 0.000 description 5
- 102000042303 SPRING family Human genes 0.000 description 5
- 108091078185 SPRING family Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 235000019437 butane-1,3-diol Nutrition 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 238000010899 nucleation Methods 0.000 description 5
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- 102000003425 Tyrosinase Human genes 0.000 description 4
- 108060008724 Tyrosinase Proteins 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000001339 epidermal cell Anatomy 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 206010039897 Sedation Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000001587 sorbitan monostearate Substances 0.000 description 3
- 235000011076 sorbitan monostearate Nutrition 0.000 description 3
- 229940035048 sorbitan monostearate Drugs 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 244000018633 Prunus armeniaca Species 0.000 description 2
- 235000009827 Prunus armeniaca Nutrition 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 235000019866 hydrogenated palm kernel oil Nutrition 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000004200 microcrystalline wax Substances 0.000 description 2
- 235000019808 microcrystalline wax Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N 2-Ethylhexanoic acid Chemical compound CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000219317 Amaranthaceae Species 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241001414720 Cicadellidae Species 0.000 description 1
- 240000001008 Dimocarpus longan Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 235000000235 Euphoria longan Nutrition 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 241000124879 Grus leucogeranus Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 240000001463 Mertensia maritima Species 0.000 description 1
- 235000011168 Mertensia maritima Nutrition 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 244000119329 Osmunda cinnamomea Species 0.000 description 1
- 235000007889 Osmunda cinnamomea Nutrition 0.000 description 1
- 241000294177 Osmunda lancea Species 0.000 description 1
- 241000676855 Osmunda x intermedia Species 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 241000294198 Plenasium banksiifolium Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 241000294518 Todea Species 0.000 description 1
- 235000012363 Tragopogon porrifolius Nutrition 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- IYNDLOXRXUOGIU-LQDWTQKMSA-M benzylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 IYNDLOXRXUOGIU-LQDWTQKMSA-M 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- SHZIWNPUGXLXDT-UHFFFAOYSA-N caproic acid ethyl ester Natural products CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 229940021231 clearskin Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9741—Pteridophyta [ferns]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Definitions
- Moisturizer cell activator, whitening agent, neutral fat accumulation inhibitor, antioxidant, and topical skin preparation
- the present invention relates to a humectant, a cell activator, a whitening agent, a neutral fat accumulation inhibitor, an antioxidant, and an external preparation for skin, which comprise a naturally derived component as an active ingredient. For more information, click here
- the present invention relates to a moisturizer, a cell activator, a whitening agent, a neutral fat accumulation inhibitor, an antioxidant, and a skin external preparation containing a plant extract.
- orchidaceae plants see JP 2002-205933
- agar extract see JP 2002-193820
- peanut seed coat extract JP 2002-14575
- psyllium extract see JP 2002-145756 A
- longan seed extract see JP 2002-145732 A
- leafhopper extract see JP 2002-14573 1).
- the present invention relates to a moisturizer, cell activator, whitening agent, neutral fat accumulation inhibitor, comprising one or more plants selected from genus genus or an extract thereof as an active ingredient, Or relates to antioxidants.
- Another aspect of the present invention relates to a skin external preparation characterized by containing one or two or more kinds of plants selected from the genus genus plants or extracts thereof.
- a moisturizer, cell activator, whitening agent having an excellent effect can be obtained by using one or two or more plants selected from the genus genus plant or an extract thereof as an active ingredient.
- Agents, neutral fat accumulation inhibitors, and antioxidants can be provided.
- moisturizers When these moisturizers, cell activators, whitening agents, neutral fat accumulation inhibitors, and antioxidants are added to skin external preparations such as cosmetics and external medicines, wrinkles, tarmi, reduced skin elasticity, It is possible to provide various compositions that exhibit excellent effects in preventing and improving the appearance of various skin symptoms such as dullness.
- Osmundaceae plant is a primitive fern plant, and the genus Osm unda, Todea, and Lentonteris are known.
- Osmunda plants include: Osmunda iaponica, Osmunda reealis, Osmunda lancea, Osmunda intermedia, Osmunda cinnamomea, Omunda cinnamomea, mundo clavtoniana) and Osmunda banksiifolia are known.
- any part such as a spore body or gametophyte root, stem, trunk, leaf, or young shoot, which is not particularly limited, can be used. Use multiple parts in combination.
- any part of the spirophytes or gametophytes of the oyster family can be used.
- the whole plant, root, leaf blade, petiole, etc. of the spore body can be used. Good.
- an extract may be obtained using a plurality of parts. You can also use a mixture of two or more extracts extracted using different solvents.
- the plant may be used as it is. However, considering the extraction efficiency, it is preferable to perform the extraction after processing such as shredding, drying, and powdering.
- the extraction can be performed by immersing in an arbitrary extraction solvent for a predetermined time.
- the extraction solvent may be heated as necessary.
- extraction can be performed using a supercritical fluid or a subcritical fluid.
- the mixture may be stirred or homogenized in an extraction solvent.
- the extraction temperature is suitably about 5 ° C to the boiling point of the extraction solvent.
- Extraction solvents include water, lower alcohols such as methanol, ethanol, propanol, and isopropanol; polyhydric alcohols such as 1,3-butylene glycol, propylene glycol, dipropylene glycol, and glycerine; ethyl ether, propyl ether Solvents such as ethers such as butyl acetate, butyl acetate, ethyl acetate and the like; ketones such as acetone, ethylmethyl ketone and the like can be used. These may be used alone or in combination of any two or more. Saline, phosphate buffer, phosphate buffered saline and the like may be used. In addition, one or more supercritical liquids such as water, carbon dioxide, ethylene, propylene, ethanol, methanol, ammonia, etc. A field liquid may be used.
- the extract of the oyster family plant using the above-mentioned solvent may be used as it is. It may be left as it is for a certain period of time to be aged, or the concentrated and dried product may be used again as water or a polar solvent. It can also be used by dissolving. Alternatively, it may be used after performing purification treatment such as decolorization, deodorization and desalting, and fractionation treatment by column chromatography or the like within the range not impairing these physiological functions.
- the above-mentioned extracts of the oyster family plants and their treated products and fractions can be freeze-dried after each treatment and fractionation and dissolved in a solvent at the time of use. Moreover, it can also be used by being encapsulated in vesicles such as ribosomes, microcapsules and the like.
- the genus plant or extract thereof has an excellent moisturizing action, cell activation action, whitening action, neutral fat accumulation inhibiting action, antioxidant action, moisturizing agent, cell activator, whitening agent, neutrality It can be used as a fat accumulation inhibitor and an antioxidant.
- Each of these agents is not limited at all in terms of its form and the presence or absence of other components as long as it contains a genus plant or its extract as an active ingredient.
- any form such as liquid, paste, gel, solid, powder, etc. can be selected according to its use etc., and the vehicle (excipient), solvent, Other general additives (anti-oxidation agent, colorant, dispersant, etc.) can optionally be included.
- a moisturizing agent containing a spring family plant or an extract thereof as an active ingredient provides an excellent moisturizing effect on the skin and hair, etc., and also has an excellent effect on improving rough skin, fine lines, dullness and skin symptoms. Demonstrate, improve skin texture and enhance skin transparency.
- a cell activator comprising a spring family plant or an extract thereof as an active ingredient has an excellent dermal fibroblast activation effect and an epidermal cell activation effect, and exhibits an excellent cell activation effect.
- a whitening agent comprising an Amaranthaceae plant or an extract thereof as an active ingredient has an excellent melanin production inhibitory effect and tyrosinase activity inhibitory effect, and is excellent in preventing and improving pigmentation, stains, freckles, etc. Demonstrate whitening effect.
- a neutral fat accumulation inhibitor comprising a spring plant or an extract thereof as an active ingredient has an excellent neutral fat accumulation inhibitory effect and exhibits an excellent neutral fat accumulation inhibitory effect.
- An antioxidant containing an apricot family plant or an extract thereof as an active ingredient is an excellent radical. It has an excellent anti-oxidant effect and has an erasing effect of superoxide-on and superoxide-on.
- a variety of skins such as wrinkles, tarmi, stains, dullness, dryness, fine wrinkles, etc. are obtained by blending the spring power plant or its extract into a skin external preparation such as cosmetics, topical pharmaceuticals, and quasi drugs. Prevention of symptoms ⁇
- a skin external preparation such as cosmetics, topical pharmaceuticals, and quasi drugs.
- Prevention of symptoms ⁇ An external preparation for skin that exhibits an excellent improvement effect can be obtained. Therefore, it can be preferably used as, for example, a moisturizing skin external preparation or a whitening skin external preparation.
- the amount of the spring power plant or the extract thereof in the external preparation for skin can be adjusted according to the type and purpose of the external preparation for skin, but the total amount of the external preparation for skin from the viewpoint of the effect and stability.
- 0.0001 to 10.0% by mass is more preferable, 0.001 to 5.0% by mass, still more preferably 0.01 to 5% by mass. , rather more preferably is 0.1 to 5 mass 0/0.
- the dosage form of the external preparation for skin is arbitrary, and for example, various dosage forms such as lotion, emulsion, gel, cream, ointment, powder, granule, pack, patch, patch, aerosol, etc. Can be provided.
- the topical skin preparation is usually used for pharmaceuticals, quasi-drugs, skin cosmetics, hair cosmetics and cleansing agents, etc., depending on the use and necessity.
- Optional ingredients to be formulated such as water, oily ingredients, humectants, powders, pigments, emulsifiers, solubilizers, gelling agents, cleaning agents, UV absorbers, anti-inflammatory agents, thickeners, pH adjusters, Surfactants, chelating agents, drugs (medicinal ingredients), fragrances, rosin, antibacterial and antifungal agents, antioxidants, alcohols and the like can be appropriately blended.
- other moisturizers, cell activators, whitening agents, neutral fat accumulation inhibitors, antioxidants, or combinations of plants other than the genus family or extracts thereof Is also possible.
- DMEM Dulbecco's modified Eagle medium
- the medium was replaced with 1% by mass FBS-added DMEM medium to which the sample (extract) was added so as to have each concentration shown in Table 1, and further cultured for 48 hours. After removing the supernatant, replace with medium containing 400 gZmL of 3- (4,5-dimethyl-2-thiazolyl) -2,5-diphenyltetrazolium bromide (MTT) and incubate for about 2 hours did. Thereafter, the formazan produced by the opening of the tetrazolium ring was extracted with 2-propanol, and the absorbance at 550 nm was measured with a microplate reader.
- MTT 3- (4,5-dimethyl-2-thiazolyl) -2,5-diphenyltetrazolium bromide
- the absorbance at 650 nm was measured as turbidity, and the cell activation effect was evaluated by the difference between the two measured values.
- the medium containing the sample In addition to the 1 mass 0 / oFBS ⁇ Ka ⁇ DMEM medium as a negative control, using 5 mass 0 / oFBS ⁇ Ka ⁇ DMEM medium as a positive control.
- Human epidermal non-keratinized cells were seeded in 96-well microplates at 2.0 ⁇ 10 4 cells per well.
- a seeding medium commercially available Humedia-KG2 manufactured by Kurabo Industries, Ltd. was used. After culturing for 24 hours, the medium was replaced with the test medium to which the sample was added at the concentrations shown in Table 2, and further cultured for 24 hours. Next, the medium was replaced with a medium containing 100 ⁇ gZmL of 3- (4,5 dimethyl-2 thiazolyl) 2,5 diphenyltetrazolium bromide (MTT) and cultured for 2 hours. -Extracted with propanol, and the absorbance at 550 nm was measured with a microplate reader. At the same time, the absorbance at 650 nm was measured as turbidity, and the cell activation effect was evaluated by the difference between the two measured values.
- the evaluation results show the cell activation effect in the control using the medium without sample.
- Table 2 shows the relative values when 0 is assumed.
- B16 mouse melanoma cells (B16F0 cells) were seeded at a density of 1.8 ⁇ 10 4 per dish.
- the seeding medium used was Dulbecco's modified Eagle medium (DMEM) supplemented with 5% by weight urine fetal serum (FBS). After 24 hours, the medium was replaced with a sample-added medium adjusted to each concentration shown in Table 4 using a DMEM medium supplemented with 5% by mass FBS, and further cultured for 5 days. After completion of the culture, the cells were detached with trypsin, transferred to a 1.5 mL microtube, and centrifuged to obtain a cell precipitate. The color of the obtained precipitate was visually judged based on the judgment table shown in Table 3.
- DMEM Dulbecco's modified Eagle medium
- FBS urine fetal serum
- the evaluation is based on a five-point scale.
- DMEM medium containing 5% FBS without sample added to the negative control (judgment 5) and 50 mM sodium lactate contained in the positive control (judgment 1) DMEM containing 5 mass 0 / oFBS Medium was used.
- the cells were completely lysed by exchanging with 75 L of 1% by mass Triton-X-containing phosphate buffer, and 50 / zL of the cell was used as a crude enzyme solution.
- 0.05 mass% L-dopa-containing phosphate buffer solution 50 / zL as a substrate was added and allowed to stand at 37 ° C. for 2 hours.
- Microplate reader 4 immediately after substrate addition and at the end of the reaction Absorbance at 05 nm was measured, and the amount of dopamelanin produced was determined by introducing each measured value into Equation (1).
- the amount of protein in each well was measured using BIER Protein Assay Kit manufactured by PIERCE, and the amount of dopamelanin produced per unit protein was determined.
- the measurement results are shown in Table 5 according to the inhibition rate based on the value of the control using the culture medium without sample.
- Subcutaneous fat-derived normal human preadipocytes Cryo ⁇ HPRAD SQ (Sanko Junyaku Co., Ltd.) were seeded on a 96-well microphone mouthplate so that there were 1.0 ⁇ 10 4 cells per well.
- PGM medium (10% by weight urinary fetal serum (FBS), 2 mM L Glutamine, 1 OOunits / mL Penicilline, 100 ⁇ g Z mL Streptomycine3 ⁇ 4′3 ⁇ 4) was used.
- PGM-diluted medium supplemented with the sample concentrations shown in Table 6 (10 ⁇ g / mL insulin, 1 M Dexamethasone, 200 ⁇ Indomethacin, 50 0 M Isobutyl—containing methylxanthine) to induce differentiation into adipocytes.
- the cells were cultured for 10 to 14 days until the control group matured and many lipid droplets accumulated in the cells. After the cells were collected, the cells were fixed using 10% neutral buffered formaldehyde solution. After washing with PBS, 0.5 wZv% Oil Red O solution was added and incubated at 37 ° C for 2 hours.
- the concentration of each sample was adjusted with 50% by mass ethanol to obtain a sample solution, and 100 / zL was added to a 96-well microplate so that the concentrations shown in Table 7 were obtained. Thereto, 0.2 mM of 1,1-diphenyl-2-picrylhydrazyl (DPPH) ethanol solution was added in an amount of 100 ⁇ L, mixed well, and allowed to stand at room temperature in the dark for 24 hours. Thereafter, the absorbance at 516 nm derived from the DPPH radical was measured.
- the extinction rate of DPPH radicals is defined as (A) where the absorbance of the control when the sample is added and when the force is applied is (B) and the absorbance when the sample is added is (B). Introduced into equation (2). The results are shown in Table 7.
- Windmill plant extract (Preparation method 1) 3.0 Production method: Heat-dissolve the oil phase components of (1) to (6) at 80 ° C. On the other hand, the aqueous phase components (7) to (10) are heated and dissolved at 80 ° C. The oil phase component is added to this while stirring and uniformly emulsified with a homogenizer. After emulsification, start cooling and add (11) and (12) in order to make uniform To mix.
- Windmill plant extract (Preparation method 3) 5.0 Production method: Dissolve (2) and (3) in (1). After dissolution, add (4) to (8) sequentially, then stir well, add (9), and mix uniformly.
- Windmill plant extract (Preparation method 1) 5.0 Production method: Heat-dissolve the oil phase components of (1) to (6) at 80 ° C. On the other hand, the aqueous phase components (7) to (10) are heated and dissolved at 80 ° C. The oil phase component is added to this while stirring and uniformly emulsified with a homogenizer. After the emulsification, add (11) and start cooling at 40 ° C (12) And mix evenly.
- Windmill plant extract (Preparation method 2) 50 Manufacturing method: Mix the aqueous phase components (1) to (6) and dissolve at 75 ° C with heating. On the other hand, the oil phase components (7) to (14) are mixed and dissolved by heating at 75 ° C. Next, the oil phase component is added to the aqueous phase component and preliminary emulsification is performed, followed by uniform emulsification with a homomixer. Start cooling after emulsification and cover (15) at 50 ° C. Cool to 40 ° C, add (16), and mix evenly.
- Windmill plant extract (Preparation method 3) 4.0 Production method: Dissolve (1) and (2) uniformly. Add (3) and (4) to this, and mix evenly.
- Windmill plant extract (Preparation method 3) 5.0 Production method: The oil phase components (1) to (4) are heated and dissolved at 80 ° C. On the other hand, the water phase components (5) to (7) are heated and dissolved at 80 ° C, and the oil phase components are mixed and stirred uniformly. Start cooling at 40 ° C Add (8) and mix evenly.
- Windmill plant extract (Preparation method 2) 3.0 Manufacturing method: Mix the oil phase components of (1) to (4), and dissolve by heating at 75 ° C. On the other hand, the aqueous phase components (5) to (7) are mixed and dissolved by heating at 75 ° C. The pigments (8) to (10) are added to this and uniformly dispersed with a homomixer. Let The oil phase component is added to the water phase component and emulsified with a homomixer. Start cooling after emulsification, add ingredients (11) and (12) at 40 ° C and mix evenly.
- Windmill plant extract (Preparation method 1) 4.0 Production method: Mix the oil phase components (1) to (6) and dissolve at 75 ° C with heating. On the other hand, the water phase components (7) to (10) are mixed and dissolved by heating at 75 ° C. The pigments (11) to (15) are added to this and uniformly dispersed with a homomixer. To do. Add oil phase ingredients and emulsify. Cooling is started after emulsification, and components (16) and (17) are sequentially added at 40 ° C and mixed uniformly.
- Example 3 A use test using the external preparation for skin of Example 3 was carried out, and the moisturizing property of the spring plant extract was evaluated. At that time, the genus plant extract formulated in Example 1 was replaced with a 50% mass ethanol aqueous solution, and the genus plant extract formulated in Comparative Example 1 and Example 3 was replaced with a 50% mass ethanol aqueous solution. A test was conducted in the same manner as Comparative Example 2 using the sample.
- Each sample has rough skin, smooth skin, and clear skin! / A group of 20 to 50-year-old male and female panelists who have troubles. Each was used for 1 month with blinds, and changes in skin condition before and after use were observed and evaluated. As indicators of skin condition, rough skin, skin texture and skin transparency were evaluated in three stages: “Improved”, “Slightly improved” and “No change”. The rough skin and the transparency of the skin were evaluated visually, and the texture of the skin was observed using a microscope. Table 10 shows the number of panelists that obtained each evaluation.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to a moisturizing agent, a cell-activating agent, a skin-whitening agent, an agent for suppressing triglyceride accumulation and an antioxidant containing as an active ingredient, one or more plants selected from plants belonging to the Osmundaceae family or an extract therefrom. Further, an external preparation for skin containing one or more plants selected from plants belonging to the Osmundaceae family or an extract therefrom is disclosed.
Description
明 細 書 Specification
保湿剤、細胞賦活剤、美白剤、中性脂肪蓄積抑制剤、抗酸化剤、及び皮 膚外用剤 Moisturizer, cell activator, whitening agent, neutral fat accumulation inhibitor, antioxidant, and topical skin preparation
技術分野 Technical field
[0001] 本発明は、天然由来成分を有効成分とする保湿剤、細胞賦活剤、美白剤、中性脂 肪蓄積抑制剤、抗酸化剤、及び皮膚外用剤に関する。さら〖こ詳しくは、ゼンマイ科( The present invention relates to a humectant, a cell activator, a whitening agent, a neutral fat accumulation inhibitor, an antioxidant, and an external preparation for skin, which comprise a naturally derived component as an active ingredient. For more information, click here
Osmundaceae)植物抽出物を含有する保湿剤、細胞賦活剤、美白剤、中性脂肪蓄 積抑制剤、抗酸化剤、及び皮膚外用剤に関する。 Osmundaceae) The present invention relates to a moisturizer, a cell activator, a whitening agent, a neutral fat accumulation inhibitor, an antioxidant, and a skin external preparation containing a plant extract.
背景技術 Background art
[0002] 加齢、疾患、ストレス、紫外線などによるシヮ、シミ、皮膚の弾力低下といった皮膚症 状の要因として、乾燥、細胞機能機能低下、紫外線によるメラニン産生や色素沈着、 真皮マトリックス成分の減少や変性、紫外線等による細胞の酸化障害などが挙げられ る。このような皮膚症状を防止 *改善するために、様々な有効成分の検索及び配合検 討がなされてきた。特に天然由来成分は、様々な薬理作用や美容効果を有すること が知られ、これまでにも数多くの植物や菌類などの抽出物の皮膚外用剤への応用が 検討されてきた。 [0002] As factors of dermatoses such as aging, disease, stress, UV blemishes, blemishes, reduced skin elasticity, dryness, decreased cellular function, melanin production and pigmentation due to UV rays, decrease in dermal matrix components And cell oxidative damage due to degeneration, ultraviolet rays and the like. In order to prevent and improve such skin symptoms, various active ingredients have been searched and compounded. In particular, naturally derived ingredients are known to have various pharmacological and cosmetic effects, and so far the application of extracts such as plants and fungi to skin preparations has been studied.
[0003] 例えば、保湿剤としてラン科植物(特開 2002— 205933号公報参照)、ァガべ抽出 物(特開 2002— 193820号公報参照)、落花生種皮の抽出物(特開 2002— 14575 7号公報参照)、サイリウム抽出物(特開 2002— 145756号公報参照)、竜眼種子の 抽出物(特開 2002— 145732号公報参照)、ォォバコ抽出物(特開 2002— 14573 1号公報参照)が知られている。細胞賦活剤としてボンカンのエッセンス(特開 2001 131045号公報参照)、美白剤として白鶴霊芝の水及び Z又は有機溶媒抽出物( 特開 2003— 89630号公報参照)、中性脂肪蓄積抑制剤としてシッポゴケ属植物の 抽出物(特開 2004— 331580号公報参照)、抗酸化剤としてサルォガセ科サルォガ セ属植物の抽出物(特開平 10— 182413号公報参照)が知られている。 [0003] For example, orchidaceae plants (see JP 2002-205933), agar extract (see JP 2002-193820), peanut seed coat extract (JP 2002-14575 7) as moisturizers. No. 2), psyllium extract (see JP 2002-145756 A), longan seed extract (see JP 2002-145732 A), and leafhopper extract (see JP 2002-14573 1). Are known. The essence of bonkan as cell activator (see JP 2001131045), water and Z or organic solvent extract of white crane reishi as whitening agent (see JP 2003-89630), neutral fat accumulation inhibitor An extract of a plant belonging to the genus Shippogoke (see JP-A-2004-331580) and an extract of a plant belonging to the genus Salogase family (see JP-A-10-182413) are known as antioxidants.
[0004] このように、これまでに様々な天然由来成分が応用されている。しかし、天然由来成 分の中には、未だその効果が知られていないものも数多く存在し、優れた保湿作用、
細胞賦活作用、美白作用、中性脂肪蓄積抑制作用、抗酸化作用などを有する有効 成分の開発が期待されていた。 [0004] Thus, various naturally-derived components have been applied so far. However, there are many naturally-derived components whose effects are not yet known. The development of an active ingredient having a cell activation effect, a whitening effect, a neutral fat accumulation inhibitory effect, an antioxidant effect and the like was expected.
発明の開示 Disclosure of the invention
[0005] 本発明者らは、天然由来の種々の成分について検討を行った結果、従来その効果 が知られていなカゝつたゼンマイ科植物抽出物に優れた保湿作用、細胞賦活作用、美 白作用、中性脂肪蓄積抑制作用、抗酸化作用が存在することを見出し、さらに検討 を重ねて本発明を完成させるに至った。 [0005] As a result of studying various components derived from nature, the inventors of the present invention have excellent moisturizing action, cell activation action, whitening, and the like, which are superior to the oyster family plant extract whose effects have not been known. It has been found that there are an action, a neutral fat accumulation inhibitory action, and an antioxidant action, and further studies have been made to complete the present invention.
[0006] すなわち、本発明は、ゼンマイ科植物より選ばれる 1種または 2種以上の植物また はその抽出物を有効成分とする保湿剤、細胞賦活剤、美白剤、中性脂肪蓄積抑制 剤、または抗酸化剤に関する。 [0006] That is, the present invention relates to a moisturizer, cell activator, whitening agent, neutral fat accumulation inhibitor, comprising one or more plants selected from genus genus or an extract thereof as an active ingredient, Or relates to antioxidants.
別の本発明は、ゼンマイ科植物より選ばれる 1種または 2種以上の植物またはその 抽出物を含有することを特徴とする皮膚外用剤に関する。 Another aspect of the present invention relates to a skin external preparation characterized by containing one or two or more kinds of plants selected from the genus genus plants or extracts thereof.
[0007] 本発明によれば、ゼンマイ科植物より選ばれる 1種または 2種以上の植物またはそ の抽出物を有効成分とすることにより、優れた効果を有する保湿剤、細胞賦活剤、美 白剤、中性脂肪蓄積抑制剤、および抗酸化剤を提供することができる。 [0007] According to the present invention, a moisturizer, cell activator, whitening agent having an excellent effect can be obtained by using one or two or more plants selected from the genus genus plant or an extract thereof as an active ingredient. Agents, neutral fat accumulation inhibitors, and antioxidants can be provided.
これらの保湿剤、細胞賦活剤、美白剤、中性脂肪蓄積抑制剤、抗酸化剤を化粧料 、外用医薬品等の皮膚外用剤に配合することにより、シヮ、タルミ、皮膚の弾力低下、 シミ、くすみといつた種々の皮膚症状の発現防止や改善に優れた効果を発揮する、 様々な組成物を提供することができる。 When these moisturizers, cell activators, whitening agents, neutral fat accumulation inhibitors, and antioxidants are added to skin external preparations such as cosmetics and external medicines, wrinkles, tarmi, reduced skin elasticity, It is possible to provide various compositions that exhibit excellent effects in preventing and improving the appearance of various skin symptoms such as dullness.
発明を実施するための最良の形態 BEST MODE FOR CARRYING OUT THE INVENTION
[0008] ゼンマイ科 (Osmundaceae)植物は、原始的なシダ植物であり、ゼンマイ属 (Osm unda)、トデァ属(Todea)、レプトプテリス属(Lentonteris)などが知られている。ゼ ンマイ属(Osmunda)植物 しては、ゼンマイ(Osmunda iaponica)、レガリスゼン マイ (Osmunda reealis)、ヤシャゼンマイ (Osmunda lancea)、ォォノ ヤシャゼン マイ (Osmunda intermedia)、ャマドリセンマイ (Osmunda cinnamomea)、ォ -ゼンマイ (Osmunda clavtoniana)、シロャマセンマイ (Osmunda banksiifolia )が知られている。 [0008] The Osmundaceae plant is a primitive fern plant, and the genus Osm unda, Todea, and Lentonteris are known. Osmunda plants include: Osmunda iaponica, Osmunda reealis, Osmunda lancea, Osmunda intermedia, Osmunda cinnamomea, Omunda cinnamomea, mundo clavtoniana) and Osmunda banksiifolia are known.
これらの植物は、単独で用いられるほ力、 2種以上を組み合わせて使用することも
できる。 These plants can be used alone or in combination of two or more. it can.
[0009] 本発明では、ゼンマイ科の植物であれば特に限定されな 、が、入手が比較的容易 などの理由から適切なものとして、ゼンマイ(Osmunda iaponica)が举げられる [0010] これらゼンマイ科植物を使用する際は、その使用部位には特に制限はなぐ胞子体 または配偶体の根、茎、幹、葉、若芽などの任意の部位を使用することができる。複 数の部位を組み合わせて使用してもょ 、。 [0009] In the present invention, it is not particularly limited as long as it is a member of the genus genus, but a mainspring (Osmunda iaponica) can be raised as a suitable one because it is relatively easy to obtain. [0010] When a plant is used, any part such as a spore body or gametophyte root, stem, trunk, leaf, or young shoot, which is not particularly limited, can be used. Use multiple parts in combination.
それらはそのまま粉砕して使用することもできるが、それらの部位力もの抽出物を用 、ることが好まし!/、。 They can be crushed as they are, but it is preferable to use extracts that are strong in their parts!
[0011] 抽出には、ゼンマイ科植物の胞子体、配偶体のいずれの部位を用いても構わない 力 簡便に利用するには、胞子体の全草、根、葉身、葉柄などを用いるとよい。その 際、複数の部位を用いて抽出物を得るようにしてもよい。また、異なる溶媒を用いて抽 出された抽出物を 2種以上混合して用いてもょ 、。 [0011] For extraction, any part of the spirophytes or gametophytes of the oyster family can be used. For easy use, the whole plant, root, leaf blade, petiole, etc. of the spore body can be used. Good. At that time, an extract may be obtained using a plurality of parts. You can also use a mixture of two or more extracts extracted using different solvents.
抽出の際は、植物を生のまま用いてもよいが、抽出効率を考えると、細切、乾燥、粉 碎等の処理を行った後に抽出を行うことが好ましい。 In the extraction, the plant may be used as it is. However, considering the extraction efficiency, it is preferable to perform the extraction after processing such as shredding, drying, and powdering.
抽出は、任意の抽出溶媒に所定時間浸漬して行うことができる。抽出溶媒は、必要 に応じて加温してもよい。あるいは、超臨界流体や亜臨界流体を用いた抽出方法で も行うことができる。抽出効率を上げるため、撹拌したり抽出溶媒中でホモジナイズし たりしてもよい。抽出温度としては、 5°C程度から抽出溶媒の沸点以下の温度とする のが適切である。抽出時間は、抽出溶媒の種類や抽出温度によっても異なるが、 1時 間〜 14日間程度とするのが適切である。 The extraction can be performed by immersing in an arbitrary extraction solvent for a predetermined time. The extraction solvent may be heated as necessary. Alternatively, extraction can be performed using a supercritical fluid or a subcritical fluid. In order to increase the extraction efficiency, the mixture may be stirred or homogenized in an extraction solvent. The extraction temperature is suitably about 5 ° C to the boiling point of the extraction solvent. Although the extraction time varies depending on the type of extraction solvent and the extraction temperature, it is appropriate that the extraction time be about 1 hour to 14 days.
[0012] 抽出溶媒としては、水の他、メタノール、エタノール、プロパノール、イソプロパノー ル等の低級アルコール; 1, 3—ブチレングリコール、プロピレングリコール、ジプロピ レングリコール、グリセリン等の多価アルコール;ェチルエーテル、プロピルエーテル 等のエーテル類、酢酸ブチル、酢酸ェチル等のエステル類;アセトン、ェチルメチル ケトン等のケトン類などの溶媒を用いることができる。これらは、単独で用いられるほ 力 任意の 2種以上を組み合わせて用いてもよい。生理食塩水、リン酸緩衝液、リン 酸緩衝生理食塩水等を用いてもよい。さらに、水や二酸化炭素、エチレン、プロピレ ン、エタノール、メタノール、アンモニアなどの 1種又は 2種以上の超臨界液体や亜臨
界液体を用いてもよい。 [0012] Extraction solvents include water, lower alcohols such as methanol, ethanol, propanol, and isopropanol; polyhydric alcohols such as 1,3-butylene glycol, propylene glycol, dipropylene glycol, and glycerine; ethyl ether, propyl ether Solvents such as ethers such as butyl acetate, butyl acetate, ethyl acetate and the like; ketones such as acetone, ethylmethyl ketone and the like can be used. These may be used alone or in combination of any two or more. Saline, phosphate buffer, phosphate buffered saline and the like may be used. In addition, one or more supercritical liquids such as water, carbon dioxide, ethylene, propylene, ethanol, methanol, ammonia, etc. A field liquid may be used.
[0013] ゼンマイ科植物の上記溶媒による抽出物は、そのままでも使用することができる力 一定期間そのまま放置して熟成させて用いてもよいし、濃縮、乾固した物を水や極性 溶媒に再度溶解して使用することもできる。或いは、これらの生理作用を損なわない 範囲で、脱色、脱臭、脱塩等の精製処理や、カラムクロマトグラフィー等による分画処 理を行った後に用いてもよい。ゼンマイ科植物の前記抽出物やその処理物及び分画 物は、各処理及び分画後に凍結乾燥し、用時に溶媒に溶解して用いることもできる。 また、リボソーム等のべシクルやマイクロカプセル等に内包させて用いることもできる。 [0013] The extract of the oyster family plant using the above-mentioned solvent may be used as it is. It may be left as it is for a certain period of time to be aged, or the concentrated and dried product may be used again as water or a polar solvent. It can also be used by dissolving. Alternatively, it may be used after performing purification treatment such as decolorization, deodorization and desalting, and fractionation treatment by column chromatography or the like within the range not impairing these physiological functions. The above-mentioned extracts of the oyster family plants and their treated products and fractions can be freeze-dried after each treatment and fractionation and dissolved in a solvent at the time of use. Moreover, it can also be used by being encapsulated in vesicles such as ribosomes, microcapsules and the like.
[0014] ゼンマイ科植物またはその抽出物は、優れた保湿作用、細胞賦活作用、美白作用 、中性脂肪蓄積抑制作用、抗酸化作用を有し、保湿剤、細胞賦活剤、美白剤、中性 脂肪蓄積抑制剤、抗酸化剤として利用することができる。 [0014] The genus plant or extract thereof has an excellent moisturizing action, cell activation action, whitening action, neutral fat accumulation inhibiting action, antioxidant action, moisturizing agent, cell activator, whitening agent, neutrality It can be used as a fat accumulation inhibitor and an antioxidant.
これらの各剤は、ゼンマイ科植物またはその抽出物を有効成分として含む限り、そ の形態およびその他の成分の配合の有無等については、何ら制限されない。形態に ついては、液状、ペースト状、ゲル状、固体状、粉末状等の任意の形態を、その用途 等に応じて選択でき、その形態とするために必要なビヒクル (賦形剤)、溶剤、その他 の一般的な添加剤 (酸ィ匕防止剤、着色剤、分散剤等)を任意に含むことができる。 Each of these agents is not limited at all in terms of its form and the presence or absence of other components as long as it contains a genus plant or its extract as an active ingredient. As for the form, any form such as liquid, paste, gel, solid, powder, etc. can be selected according to its use etc., and the vehicle (excipient), solvent, Other general additives (anti-oxidation agent, colorant, dispersant, etc.) can optionally be included.
[0015] ゼンマイ科植物またはその抽出物を有効成分とする保湿剤は、皮膚や毛髪等に優 れた保湿効果を与えるとともに、肌荒れ、小じわ、くすみといつた皮膚症状の改善に 優れた効果を発揮し、肌のキメを整え、肌の透明感を高めることができる。 [0015] A moisturizing agent containing a spring family plant or an extract thereof as an active ingredient provides an excellent moisturizing effect on the skin and hair, etc., and also has an excellent effect on improving rough skin, fine lines, dullness and skin symptoms. Demonstrate, improve skin texture and enhance skin transparency.
[0016] ゼンマイ科植物またはその抽出物を有効成分とする細胞賦活剤は、優れた真皮線 維芽細胞賦活効果及び表皮細胞賦活効果を有し、優れた細胞賦活作用を発揮する [0016] A cell activator comprising a spring family plant or an extract thereof as an active ingredient has an excellent dermal fibroblast activation effect and an epidermal cell activation effect, and exhibits an excellent cell activation effect.
[0017] ゼンマイ科植物またはその抽出物を有効成分とする美白剤は、優れたメラニン産生 抑制効果及びチロシナーゼ活性阻害効果を有し、色素沈着、シミ、そばかす等を予 防および改善して、優れた美白作用を発揮する。 [0017] A whitening agent comprising an Amaranthaceae plant or an extract thereof as an active ingredient has an excellent melanin production inhibitory effect and tyrosinase activity inhibitory effect, and is excellent in preventing and improving pigmentation, stains, freckles, etc. Demonstrate whitening effect.
[0018] ゼンマイ科植物またはその抽出物を有効成分とする中性脂肪蓄積抑制剤は、優れ た中性脂肪蓄積抑制効果を有し、優れた中性脂肪蓄積抑制作用を発揮する。 [0018] A neutral fat accumulation inhibitor comprising a spring plant or an extract thereof as an active ingredient has an excellent neutral fat accumulation inhibitory effect and exhibits an excellent neutral fat accumulation inhibitory effect.
[0019] ゼンマイ科植物またはその抽出物を有効成分とする抗酸化剤は、優れたラジカル
の消去効果、及びスーパーオキサイドァ-オンの消去効果を有し、優れた抗酸化作 用を発揮する。 [0019] An antioxidant containing an apricot family plant or an extract thereof as an active ingredient is an excellent radical. It has an excellent anti-oxidant effect and has an erasing effect of superoxide-on and superoxide-on.
[0020] ゼンマイ科植物またはその抽出物を、化粧品、外用医薬品、医薬部外品等の皮膚 外用剤に配合することにより、シヮ、タルミ、シミ、くすみ、乾燥、小じわ等の様々な皮 膚症状の防止 ·改善に優れた効果を発揮する皮膚外用剤を得ることができる。したが つて、たとえば、保湿用皮膚外用剤または美白用皮膚外用剤として好ましく使用する ことができる。 [0020] A variety of skins such as wrinkles, tarmi, stains, dullness, dryness, fine wrinkles, etc. are obtained by blending the spring power plant or its extract into a skin external preparation such as cosmetics, topical pharmaceuticals, and quasi drugs. Prevention of symptoms · An external preparation for skin that exhibits an excellent improvement effect can be obtained. Therefore, it can be preferably used as, for example, a moisturizing skin external preparation or a whitening skin external preparation.
[0021] ゼンマイ科植物またはその抽出物の皮膚外用剤中の配合量は、皮膚外用剤の種 類や目的等によって調整することができるが、効果や安定性などの点から、皮膚外用 剤全量に対して、固形分換算で、 0. 0001〜10. 0質量%が好ましぐより好ましくは 、 0. 001-5. 0質量%であり、さらに好ましくは 0. 01〜5質量%であり、一層好まし くは 0. 1〜5質量0 /0である。 [0021] The amount of the spring power plant or the extract thereof in the external preparation for skin can be adjusted according to the type and purpose of the external preparation for skin, but the total amount of the external preparation for skin from the viewpoint of the effect and stability. In terms of solid content, 0.0001 to 10.0% by mass is more preferable, 0.001 to 5.0% by mass, still more preferably 0.01 to 5% by mass. , rather more preferably is 0.1 to 5 mass 0/0.
[0022] 皮膚外用剤の剤型は任意であり、例えば、ローション、乳液、ゲル、クリーム、軟膏 剤、粉末、顆粒、パック剤、貼布剤、パップ剤、エアゾール剤等、種々の剤型で提供 することができる。 [0022] The dosage form of the external preparation for skin is arbitrary, and for example, various dosage forms such as lotion, emulsion, gel, cream, ointment, powder, granule, pack, patch, patch, aerosol, etc. Can be provided.
[0023] 皮膚外用剤には、ゼンマイ科植物またはその抽出物の他に、その用途と必要に応 じて、医薬品、医薬部外品、皮膚化粧料、毛髪用化粧料及び洗浄料等に通常配合 される任意の成分、たとえば水、油性成分、保湿剤、粉体、色素、乳化剤、可溶化剤 、ゲル化剤、洗浄剤、紫外線吸収剤、抗炎症剤、増粘剤、 pH調整剤、界面活性剤、 キレート剤、薬剤 (薬効成分)、香料、榭脂、防菌防かび剤、抗酸化剤、アルコール類 等を適宜配合することができる。さらに、本発明の効果を損なわない範囲において、 他の保湿剤、細胞賦活剤、美白剤、中性脂肪蓄積抑制剤、抗酸化剤、あるいはゼン マイ科植物以外の植物またはその抽出物との併用も可能である。 [0023] In addition to the genus plant or extract thereof, the topical skin preparation is usually used for pharmaceuticals, quasi-drugs, skin cosmetics, hair cosmetics and cleansing agents, etc., depending on the use and necessity. Optional ingredients to be formulated, such as water, oily ingredients, humectants, powders, pigments, emulsifiers, solubilizers, gelling agents, cleaning agents, UV absorbers, anti-inflammatory agents, thickeners, pH adjusters, Surfactants, chelating agents, drugs (medicinal ingredients), fragrances, rosin, antibacterial and antifungal agents, antioxidants, alcohols and the like can be appropriately blended. Furthermore, within the range not impairing the effects of the present invention, other moisturizers, cell activators, whitening agents, neutral fat accumulation inhibitors, antioxidants, or combinations of plants other than the genus family or extracts thereof Is also possible.
実施例 Example
[0024] 以下にゼンマイ科植物抽出物の調製例、各作用を評価するための試験、皮膚外用 剤としての処方例、使用試験についてさらに詳細に説明するが、本発明の技術的範 囲はこれによってなんら限定されるものではない。 [0024] Hereinafter, preparation examples of spring plant extracts, tests for evaluating each action, formulation examples as a topical skin preparation, and use tests will be described in more detail, but the technical scope of the present invention is described below. It is not limited at all.
[0025] <調製方法 1 >
ゼンマイ (Osmunda iaponica)の胞子体全草の乾燥粉砕物 lkgに 50質量%エタ ノール水溶液を 20リットル加え、室温で 7日間浸漬した。抽出液をろ過して回収し、 溶媒を除去した後、ゼンマイ科植物抽出物 30gを得た。 <Preparation method 1> 20 liters of 50% by weight ethanol aqueous solution was added to 1 kg of dried pulverized whole plant spores of Osmunda iaponica and soaked at room temperature for 7 days. The extract was collected by filtration, and after removing the solvent, 30 g of the spring plant extract was obtained.
[0026] <調製方法 2> <Preparation method 2>
ゼンマイの胞子体全草の乾燥粉砕物 lkgに水を 20リットルカ卩え、 90°Cにて 6時間 還流して抽出した。抽出液をろ過して回収し、溶媒を除去した後、ゼンマイ科植物抽 出物 20gを得た。 Water (20 liters) was added to 1 kg of dry ground pulverized whole body of spring main body, and extracted by refluxing at 90 ° C for 6 hours. The extract was collected by filtration, and after removing the solvent, 20 g of an extract of the genus genus plant was obtained.
[0027] <調製方法 3 > <Preparation method 3>
ゼンマイの胞子体全草の乾燥粉砕物 lkgにメタノール 20リットルカ卩え、室温で 7日 間浸漬した。抽出液をろ過して回収し、溶媒を除去した後、ゼンマイ科植物抽出物 5 Ogを得た。 20 kg of methanol was added to 1 kg of dried pulverized whole body of spring main body and immersed for 7 days at room temperature. The extract was collected by filtration, and after removing the solvent, a spring extract 5 Og was obtained.
[0028] <調製方法 4> <Preparation method 4>
超臨界抽出装置にゼンマイの胞子体全草の乾燥粉砕物 100gを投入し、 40°Cにお いて 15Mpaの大気圧下で二酸ィ匕炭素の超臨界流体を用いて抽出した。抽出物を回 収し、ゼンマイ科植物抽出物 10gを得た。 100 g of dry pulverized whole body of a spring spring sprout was put into a supercritical extraction device, and extracted using a supercritical fluid of carbon dioxide and carbon dioxide at 40 ° C under an atmospheric pressure of 15 MPa. The extract was recovered to obtain 10 g of a spring family plant extract.
[0029] <細胞賦活作用の評価 1 (真皮線維芽細胞賦活作用) > [0029] <Evaluation of cell activation 1 (dermal fibroblast activation)>
ゼンマイ科植物抽出物の真皮線維芽細胞賦活作用の評価を、以下に示す方法に より行った。試料として、調製方法 1により製造したゼンマイ科植物抽出物を用いた。 クラボウ社 (倉敷紡績株式会社)製正常ヒト真皮線維芽細胞を、 1ゥエル当たり 2. 0 X 104個となるように 96穴マイクロプレートに播種した。播種培地には、ダルベッコ改 変イーグル培地(DMEM)に 1質量%のゥシ胎児血清 (FBS)を添カ卩したものを用い た。 24時間培養後、表 1に示す各濃度となるように試料 (抽出物)を添加した 1質量% FBS添加 DMEM培地に交換し、さらに 48時間培養した。上清を除いた後、 3— (4, 5—ジメチルー 2—チアゾリル)—2, 5—ジフエ-ルテトラゾリゥムブロミド(MTT)を 40 0 gZmL含有する培地に交換して約 2時間培養した。その後、テトラゾリゥム環の 開環により生じるフオルマザンを 2—プロパノールにて抽出し、マイクロプレートリーダ 一にて 550nmの吸光度を測定した。同時に、濁度として 650nmにおける吸光度を 測定し、両測定値の差により細胞賦活作用を評価した。評価では、試料を含む培地
の他に、ネガティブコントロールとして 1質量0 /oFBS添カ卩 DMEM培地を、ポジティブ コントロールとして 5質量0 /oFBS添カ卩 DMEM培地を用いた。 Evaluation of the dermal fibroblast activation action of the springfish plant extract was performed by the following method. As a sample, a genus plant extract produced by Preparation Method 1 was used. Normal human dermal fibroblasts manufactured by Kurabo Industries Co., Ltd. (Kurashiki Boseki Co., Ltd.) were seeded in a 96-well microplate so as to be 2.0 × 10 4 per well. The seeding medium used was Dulbecco's modified Eagle medium (DMEM) supplemented with 1% by weight urchin fetal serum (FBS). After culturing for 24 hours, the medium was replaced with 1% by mass FBS-added DMEM medium to which the sample (extract) was added so as to have each concentration shown in Table 1, and further cultured for 48 hours. After removing the supernatant, replace with medium containing 400 gZmL of 3- (4,5-dimethyl-2-thiazolyl) -2,5-diphenyltetrazolium bromide (MTT) and incubate for about 2 hours did. Thereafter, the formazan produced by the opening of the tetrazolium ring was extracted with 2-propanol, and the absorbance at 550 nm was measured with a microplate reader. At the same time, the absorbance at 650 nm was measured as turbidity, and the cell activation effect was evaluated by the difference between the two measured values. In the evaluation, the medium containing the sample In addition to the 1 mass 0 / oFBS添Ka卩DMEM medium as a negative control, using 5 mass 0 / oFBS添Ka卩DMEM medium as a positive control.
評価結果を、ネガティブコントロールにおける細胞賦活作用を 100とした相対値とし て、表 1に示す。 The evaluation results are shown in Table 1 as relative values with the cell activation effect in the negative control as 100.
[表 1] [table 1]
[0031] 表 1より明らかなように、ゼンマイ科植物抽出物を添加した培地では、有意な真皮線 維芽細胞賦活効果が認められた。このことから、ゼンマイ科植物抽出物は、優れた真 皮線維芽細胞賦活作用を有することが明らかとなった。 [0031] As is clear from Table 1, a significant dermal fibroblast activation effect was observed in the medium supplemented with the spring plant extract. From this, it has been clarified that the spring-like plant extract has an excellent dermal fibroblast activation effect.
[0032] <細胞賦活作用の評価 2 (表皮細胞賦活作用) > [0032] <Evaluation of cell activation 2 (epidermal cell activation)>
ゼンマイ科植物抽出物の表皮細胞賦活作用の評価を、以下に示す方法により行つ た。試料として、調製方法 2により製造したゼンマイ科植物抽出物を用いた。 Evaluation of the epidermis cell activation effect of the springfish plant extract was performed by the method shown below. As a sample, a genus plant extract produced by Preparation Method 2 was used.
ヒト表皮未全角化細胞を、 1ゥエル当たり 2. 0 X 104個となるように 96穴マイクロプレ ートに播種した。播種培地には、市販のクラボウ社製 Humedia—KG2を用いた。 24 時間培養後、表 2に示す濃度で試料を添加した試験培地に交換し、さらに 24時間培 養した。次いで、 3— (4, 5 ジメチルー 2 チアゾリル ) 2, 5 ジフエ-ルテトラゾリ ゥムブロミド (MTT)を 100 μ gZmL含有する培地に交換して 2時間培養した後、テト ラゾリゥム環の開環により生じるフオルマザンを 2 -プロパノールにて抽出し、マイクロ プレートリーダーにて 550nmの吸光度を測定した。同時に、濁度として 650nmにお ける吸光度を測定し、両測定値の差により細胞賦活作用を評価した。 Human epidermal non-keratinized cells were seeded in 96-well microplates at 2.0 × 10 4 cells per well. As a seeding medium, commercially available Humedia-KG2 manufactured by Kurabo Industries, Ltd. was used. After culturing for 24 hours, the medium was replaced with the test medium to which the sample was added at the concentrations shown in Table 2, and further cultured for 24 hours. Next, the medium was replaced with a medium containing 100 μgZmL of 3- (4,5 dimethyl-2 thiazolyl) 2,5 diphenyltetrazolium bromide (MTT) and cultured for 2 hours. -Extracted with propanol, and the absorbance at 550 nm was measured with a microplate reader. At the same time, the absorbance at 650 nm was measured as turbidity, and the cell activation effect was evaluated by the difference between the two measured values.
評価結果を、試料無添加の培地を用いたコントロールにおける細胞賦活作用を 10
0とした場合の相対値として、表 2に示す。 The evaluation results show the cell activation effect in the control using the medium without sample. Table 2 shows the relative values when 0 is assumed.
[0033] [表 2] [0033] [Table 2]
[0034] 表 2より明らかなように、ゼンマイ科植物抽出物を添加した培地では、有意な表皮細 胞賦活効果が認められた。このことから、ゼンマイ科植物抽出物は、優れた表皮細胞 賦活作用を有することがわ力つた。 [0034] As is clear from Table 2, a significant epidermal cell activation effect was observed in the medium supplemented with the oyster family plant extract. From this, it has been proved that the plant spring plant extract has an excellent epidermal cell activation effect.
以上のことから、ゼンマイ科植物抽出物は,優れた細胞賦活作用を有することが明 らかとなつた。 Based on the above, it has been clarified that the oyster plant extract has an excellent cell activation effect.
[0035] <美白作用の評価 1 (メラニン産生抑制作用) > [0035] <Evaluation of whitening action 1 (melanin production inhibitory action)>
ゼンマイ科植物抽出物のメラニン産生抑制作用の評価を、以下に示す方法により 行った。試料として、調製方法 3により製造したゼンマイ科植物抽出物を用いた。 Evaluation of the melanin production inhibitory effect of the springfish plant extract was performed by the following method. As a sample, a genus plant extract produced by Preparation Method 3 was used.
B16マウスメラノーマ細胞(B16F0細胞)を、 1ディッシュ当り 1. 8 X 104個となるよう に播種した。播種培地にはダルベッコ改変イーグル培地(DMEM)に 5質量%ゥシ 胎児血清 (FBS)を添加したものを用いた。 24時間後、 5質量%FBS添加 DMEM培 地により表 4に示す各濃度に調整した試料添加培地に交換し、さらに 5日間培養した 。培養終了後、トリプシンにより細胞を剥離し、 1. 5mLマイクロチューブに移して遠心 操作して、細胞沈殿物を得た。得られた沈殿物の色を、表 3に示す判定表に基づい て目視判定した。評価は 5段階評価とし、ネガティブコントロール (判定 5)に試料無添 加の 5質量%FBS添カ卩 DMEM培地、ポジティブコントロール(判定 1)に乳酸ナトリウ ムを 50mM含有する 5質量0 /oFBS添加 DMEM培地を用いた。 B16 mouse melanoma cells (B16F0 cells) were seeded at a density of 1.8 × 10 4 per dish. The seeding medium used was Dulbecco's modified Eagle medium (DMEM) supplemented with 5% by weight urine fetal serum (FBS). After 24 hours, the medium was replaced with a sample-added medium adjusted to each concentration shown in Table 4 using a DMEM medium supplemented with 5% by mass FBS, and further cultured for 5 days. After completion of the culture, the cells were detached with trypsin, transferred to a 1.5 mL microtube, and centrifuged to obtain a cell precipitate. The color of the obtained precipitate was visually judged based on the judgment table shown in Table 3. The evaluation is based on a five-point scale. DMEM medium containing 5% FBS without sample added to the negative control (judgment 5) and 50 mM sodium lactate contained in the positive control (judgment 1) DMEM containing 5 mass 0 / oFBS Medium was used.
また、メラニン産生量を評価するために、沈殿物に Soluen— 350 (株式会社パーキ ンエルマ一ジャパン)を加えて煮沸し、分光光度計((株)日立ハイテクノロジーズ製 分光光度計 U— 3010)により 500nmにおける吸光度を測定した。 In order to evaluate the amount of melanin produced, add Soluen-350 (Perkin Elma Japan Co., Ltd.) to the precipitate and boil it, then use a spectrophotometer (Spectrophotometer U-3010 manufactured by Hitachi High-Technologies Corporation). Absorbance at 500 nm was measured.
得られた結果を表 4に示す。
[0036] [表 3] The results obtained are shown in Table 4. [0036] [Table 3]
[0037] [表 4] [0037] [Table 4]
[0038] 表 4より明らかなように、ゼンマイ科植物抽出物を添加した培地では、有意なメラ- ン産生抑制効果が認められた。このことから、ゼンマイ科植物抽出物は、優れたメラ ニン産生抑制作用を有することがわ力つた。 [0038] As is clear from Table 4, in the medium supplemented with the oyster family plant extract, a significant melanogenesis inhibitory effect was observed. From this, it has been proved that the plant spring plant extract has an excellent inhibitory effect on melanin production.
[0039] <美白作用の評価 2 (チロシナーゼ活性阻害作用) > [0039] <Evaluation of whitening action 2 (Tyrosinase activity inhibitory action)>
ゼンマイ科植物抽出物のチロシナーゼ活性阻害作用の評価を、以下に示す方法 により行った。試料として、調製方法 1により製造したゼンマイ科植物抽出物を用いた クラボウ社製正常ヒト表皮メラニン細胞を、 1ゥエル当たり 3. 0 X 104個となるように 9 6ウェルマイク口プレートに播種した。播種培地には、クラボウ社製 Mediuml54Sを 用いた。 24時間後、 Mediuml54Sによって表 5に示す各濃度に調整した試料添カロ 培地に交換し、さら〖こ 48時間培養した。次に、 1質量%Triton— X含有リン酸緩衝液 75 Lに交換して細胞を完全に溶解させ、内 50 /z Lを粗酵素液として使用した。粗 酵素液に、基質となる 0. 05質量%L—ドーパ含有リン酸緩衝液 50 /z Lをカ卩え、 37°C で 2時間静置した。マイクロプレートリーダーにより、基質添加直後と反応終了時の 4
05nmの吸光度を測定し、生成されたドーパメラニン量を、式(1)に各測定値を導入 して求めた。 Evaluation of the tyrosinase activity inhibitory action of the oyster family plant extracts was carried out by the following method. As a sample, normal human epidermal melanocytes manufactured by Kurabo Industries using the genus genus plant produced by Preparation Method 1 were seeded in 9 6-well microphone mouthplates at 3.0 x 10 4 per well. . As the seeding medium, Mediuml 54S manufactured by Kurabo Industries was used. After 24 hours, the sample-added caro culture medium adjusted to each concentration shown in Table 5 was exchanged with Medium 54S, and cultured for 48 hours. Next, the cells were completely lysed by exchanging with 75 L of 1% by mass Triton-X-containing phosphate buffer, and 50 / zL of the cell was used as a crude enzyme solution. In the crude enzyme solution, 0.05 mass% L-dopa-containing phosphate buffer solution 50 / zL as a substrate was added and allowed to stand at 37 ° C. for 2 hours. Microplate reader 4 immediately after substrate addition and at the end of the reaction Absorbance at 05 nm was measured, and the amount of dopamelanin produced was determined by introducing each measured value into Equation (1).
式(1): 生成されたドーパメラニン量 = { (反応後 405nm値-反応前 405nm 値"— 2. 166/5. 238 Formula (1): Amount of produced dopamelanin = {(After reaction 405 nm value-Before reaction 405 nm value "— 2. 166/5. 238
また、 PIERCE社製 BCA Protein Assay Kitにより各ゥエルのタンパク量を測 定し、単位タンパク量当たりのドーパメラニン生成量を求めた。測定結果を、試料無 添カ卩の培地を用いたコントロールの値を基準として、阻害率により表 5に示す。 The amount of protein in each well was measured using BIER Protein Assay Kit manufactured by PIERCE, and the amount of dopamelanin produced per unit protein was determined. The measurement results are shown in Table 5 according to the inhibition rate based on the value of the control using the culture medium without sample.
[0040] [表 5] [0040] [Table 5]
[0041] 表 5より明らかなように、ゼンマイ科植物抽出物を添加した培地を用いた場合には、 メラニン産生量の低下が認められた。このことより、ゼンマイ科植物抽出物は、優れた チロシナーゼ活性阻害作用を有することがわ力つた。 [0041] As is clear from Table 5, when the medium supplemented with the oyster family plant extract was used, a decrease in melanin production was observed. From this fact, it has been proved that the oyster family plant extract has an excellent tyrosinase activity inhibitory action.
以上のことから、ゼンマイ科植物抽出物は、優れた美白作用を有することが明らかと なった。 From the above, it has been clarified that the spring-like plant extract has an excellent whitening effect.
[0042] <中性脂肪蓄積抑制作用の評価 > [0042] <Evaluation of neutral fat accumulation inhibitory effect>
ゼンマイ科植物抽出物の脂肪細胞における中性脂肪蓄積抑制作用の評価を、以 下に示す方法により行った。試料として、調製方法 1により製造したゼンマイ科植物 抽出物を用いた。 Evaluation of the neutral fat accumulation-inhibiting action of the apricot family plant extract in adipocytes was performed by the following method. As a sample, a genus genus plant extract produced by Preparation Method 1 was used.
皮下脂肪由来正常ヒト前駆脂肪細胞 Cryo · HPRAD SQ (三光純薬株式会社) を、 1ゥエル当り 1. 0 X 104個となるように 96ウェルマイク口プレートに播種した。播種 培地には、 PGM培地(10質量%ゥシ胎児血清(FBS) , 2mM L Glutamine, 1 OOunits/ mL Penicilline, 100 μ gZ mL Streptomycine¾'¾ ) 用いた。糸田 胞が飽和状態になる直前に表 6に示す濃度の試料を添加した PGM分ィ匕用培地(10 μ g/mL インシュリン, 1 M Dexamethasone, 200 μ Μ Indomethacin, 50
0 M Isobutyl— methylxanthine含有)に交換し、脂肪細胞への分化誘導を行 つた。分化誘導開始後、コントロール群が成熟して細胞内に多数の脂肪滴が蓄積さ れるまで、 10日〜 14日間培養した。細胞を回収後、 10%中性緩衝ホルムアルデヒド 液を用いて細胞を固定した。 PBSにて洗浄の後、 0. 5wZv%オイルレッド O溶液を 添加し、 37°Cで 2時間インキュベートした。 PBSにて洗浄の後、メタノールを添カロし、 色素を抽出した。抽出後、マイクロプレートリーダーにより、 550nmの吸光度を測定し た。同時に、濁度として 650nmの吸光度を測定し、両測定値の差を用いて中性脂肪 蓄積量を測定した。 Subcutaneous fat-derived normal human preadipocytes Cryo · HPRAD SQ (Sanko Junyaku Co., Ltd.) were seeded on a 96-well microphone mouthplate so that there were 1.0 × 10 4 cells per well. As the seeding medium, PGM medium (10% by weight urinary fetal serum (FBS), 2 mM L Glutamine, 1 OOunits / mL Penicilline, 100 μg Z mL Streptomycine¾′¾) was used. Immediately before Ito's saturation is reached, PGM-diluted medium supplemented with the sample concentrations shown in Table 6 (10 μg / mL insulin, 1 M Dexamethasone, 200 μΜ Indomethacin, 50 0 M Isobutyl—containing methylxanthine) to induce differentiation into adipocytes. After initiation of differentiation induction, the cells were cultured for 10 to 14 days until the control group matured and many lipid droplets accumulated in the cells. After the cells were collected, the cells were fixed using 10% neutral buffered formaldehyde solution. After washing with PBS, 0.5 wZv% Oil Red O solution was added and incubated at 37 ° C for 2 hours. After washing with PBS, methanol was added to extract the pigment. After extraction, the absorbance at 550 nm was measured with a microplate reader. At the same time, the absorbance at 650 nm was measured as turbidity, and the amount of triglyceride accumulated was measured using the difference between the two measurements.
測定結果を、試料無添加の培地を用いたコントロールにおける、中性脂肪蓄積量 を 100とした相対値により、表 6に示す。 The measurement results are shown in Table 6 in terms of relative values with the neutral fat accumulation amount set to 100 in the control using the medium without the sample.
[0043] [表 6] [0043] [Table 6]
[0044] 表 6より明らかなように、ゼンマイ科植物抽出物を添加した培地では、有意な中性脂 肪蓄積抑制効果が認められた。このことから、ゼンマイ科植物抽出物は、優れた中性 脂肪蓄積抑制作用を有することが明らかとなった。 [0044] As is clear from Table 6, a significant neutral fat accumulation inhibitory effect was observed in the culture medium supplemented with the oyster family plant extract. From this, it has been clarified that the spring-like plant extract has an excellent neutral fat accumulation inhibitory action.
[0045] <抗酸化作用の評価 1 (ラジカル消去作用) > [0045] <Evaluation of antioxidant action 1 (radical scavenging action)>
ゼンマイ科植物抽出物の抗酸化作用の評価を、以下に示す方法により行った。試 料として、調製方法 1により製造したゼンマイ科植物抽出物を用いた。 Evaluation of the antioxidant effect of the springfish plant extract was performed by the following method. As a sample, a genus plant extract produced by Preparation Method 1 was used.
各試料を、 50質量%エタノールを用いて濃度調整して試料溶液とし、表 7に示す濃 度となるように 96穴マイクロプレートに 100 /z Lずつ添カ卩した。そこへ、 0. 2mMの 1, 1—ジフエ-ルー 2—ピクリルヒドラジル (DPPH)エタノール溶液を 100 μ Lずつ添加 し、良く混合後、室温、暗所にて 24時間静置した。その後、 DPPHラジカルに由来す る 516nmの吸光度を測定した。試料を添加しな力つた場合のコントロールの吸光度 を (A)、試料を添加した場合の吸光度を (B)としたとき、 DPPHラジカルの消去率を
式(2)に導入して求めた。結果を表 7に示す。 The concentration of each sample was adjusted with 50% by mass ethanol to obtain a sample solution, and 100 / zL was added to a 96-well microplate so that the concentrations shown in Table 7 were obtained. Thereto, 0.2 mM of 1,1-diphenyl-2-picrylhydrazyl (DPPH) ethanol solution was added in an amount of 100 μL, mixed well, and allowed to stand at room temperature in the dark for 24 hours. Thereafter, the absorbance at 516 nm derived from the DPPH radical was measured. The extinction rate of DPPH radicals is defined as (A) where the absorbance of the control when the sample is added and when the force is applied is (B) and the absorbance when the sample is added is (B). Introduced into equation (2). The results are shown in Table 7.
式 (2): ラジカル消去率 = { 1一(B) Z (A) } X 100 (%) Formula (2): Radical scavenging rate = {1 (B) Z (A)} X 100 (%)
[表 7] [Table 7]
[0047] 表 7より明らかなように、ゼンマイ科植物抽出物には優れた DPPHラジカルの消去 効果が認められた。このことより、ゼンマイ科植物抽出物は、優れたラジカルの消去 作用を有することがわ力つた。 [0047] As is clear from Table 7, an excellent DPPH radical scavenging effect was observed in the oyster family plant extract. From this, it has been proved that the genus plant extract has an excellent radical scavenging action.
[0048] く抗酸ィ匕作用の評価 2 (スーパーオキサイドァニオン消去作用) > [0048] Evaluation of anti-acidic action 2 (superoxide anion scavenging action)>
ゼンマイ科植物抽出物のスーパーオキサイドァニオン消去作用の評価を、以下に 示す方法により行った。試料として、調製方法 1により製造したゼンマイ科植物抽出 物を用いた。 Evaluation of the superoxide anion scavenging action of the springfish plant extract was carried out by the method described below. As a sample, a genus plant extract produced by Preparation Method 1 was used.
96穴マイクロプレートに、表 8に示す濃度となるように任意の濃度に希釈したゼンマ ィ抽出物の Hanks ( + )溶液 25 /z Lと、反応溶液 75 し(0. 25mM NBT, ImM Hypoxanthine, 0. ImM EDTAを含む Hanks ( + )液 (pH7. 4))を添加し、キサ ンチンォキシダーゼ溶液 25 /z I^O. 0075Units)を加え、 37°Cで 15分間インキュべ ートした。その後、マイクロプレートリーダーで 540nmの吸光度を測定した。試料無 添加のコントロールの吸光度を (A)、試料を添加したときの吸光度を (B)としたとき、 式(3)の値をラジカル消去率とした。評価結果を表 8に示した。 In a 96-well microplate, add Hanks (+) solution 25 / z L of Zeny extract diluted to any concentration as shown in Table 8, and 75 reaction solution (0.25 mM NBT, ImM Hypoxanthine, 0. Hanks (+) solution (pH7.4) containing ImM EDTA was added, xanthine oxidase solution 25 / z I ^ O.0075Units) was added, and the mixture was incubated at 37 ° C for 15 minutes. Thereafter, the absorbance at 540 nm was measured with a microplate reader. When the absorbance of the control with no sample added was (A) and the absorbance when the sample was added was (B), the value of equation (3) was taken as the radical scavenging rate. The evaluation results are shown in Table 8.
式 (3) : { 1 - (B) / (A) } X 100 (%) Formula (3): {1-(B) / (A)} X 100 (%)
[0049] [表 8]
添加濃度(mg/mL) 消去率 (%) [0049] [Table 8] Concentration (mg / mL) Erase rate (%)
コント口-ル 0 Control mouth 0
0.013 35.2 0.013 35.2
0.05 74.5 0.05 74.5
0.20 96.7 0.20 96.7
[0050] 表 8より明らかなように、ゼンマイ科植物抽出物には優れたスーパーオキサイドァ- オンの消去効果が認められた。このことより、ゼンマイ科植物抽出物は、優れたスー パーオキサイドァ-オンの消去作用を有することがわ力つた。 [0050] As can be seen from Table 8, the superior oxidization effect of superoxide ions was observed in the genus plantaceae extracts. From this, it was proved that the spring-like plant extract has an excellent superoxide-one erasing action.
以上のことから、ゼンマイ科植物抽出物は、優れた抗酸化作用を有することが明ら カゝとなった。 From the above, it has been clarified that the oyster family plant extract has an excellent antioxidant action.
[0051] 続 、て、上記各調製方法で得られたゼンマイ科植物抽出物を配合した皮膚外用剤 の処方例を示す。 [0051] Next, prescription examples of the external preparation for skin containing the extract of the spring family plant obtained by each of the above preparation methods will be shown.
[実施例 1]乳液 [Example 1] Emulsion
配合: Formula:
[表 A] [Table A]
( 1 ) スクヮラン 10. 0 (質量%)(1) Screen 10.0 (mass%)
(2) メチルフエ二ルポリシロキサン 4. 0(2) Methylphenylpolysiloxane 4.0
(3) 水素添加パーム核油 0. 5(3) Hydrogenated palm kernel oil 0.5
(4) 水素添加大豆リン脂質 0. 1(4) Hydrogenated soybean phospholipid 0.1
(5) モノステアリン酸ポリオキシエチレンソルビタン (20 E. O. ) (5) Polyoxyethylene sorbitan monostearate (20 E. O.)
1. 3 13
(6) モノステアリン酸ソルビタン 1. 0 ( 7 ) グリセリン 4. 0 (6) Sorbitan monostearate 1.0 (7) Glycerin 4.0
(8) パラォキシ安息香酸メチル 0. 1(8) Methyl paraoxybenzoate 0.1
(9) カルボキシビ二ルポリマ一 0. 1 5(9) Carboxyvinyl polymer 0.15
(10) 精製水 1 0 0とする残部(10) The balance of purified water 1 0 0
(11) アルギニン (1質量%水溶液) 2 0. 0(11) Arginine (1 wt% aqueous solution) 2 0. 0
(12) ゼンマイ科植物抽出物 (調製方法 1) 3. 0 製法:(1)〜(6)の油相成分を 80°Cにて加熱溶解する。一方(7)〜(10)の水相成分 を 80°Cにて加熱溶解する。これに前記油相成分を攪拌しながら加え、ホモジナイザ 一により均一に乳化する。乳化終了後、冷却を開始し、(11)と(12)を順次加え、均一
に混合する。 (12) Windmill plant extract (Preparation method 1) 3.0 Production method: Heat-dissolve the oil phase components of (1) to (6) at 80 ° C. On the other hand, the aqueous phase components (7) to (10) are heated and dissolved at 80 ° C. The oil phase component is added to this while stirring and uniformly emulsified with a homogenizer. After emulsification, start cooling and add (11) and (12) in order to make uniform To mix.
[実施例 2]化粧水 [Example 2] Lotion
配合: Formula:
[表 B] [Table B]
( 1 ) エタノール 1 5. 0 (質量%)(1) Ethanol 15.0 (mass%)
(2) ポリオキシエチレン (40 E. O. ) 硬化ヒマシ油 0. 3 (2) Polyoxyethylene (40 E. O.) Hardened castor oil 0.3
(3) 香料 0. 1 (3) Fragrance 0. 1
(4) 精製水 1 0 0とする残部 (4) The balance of purified water 1 0 0
(5) クェン酸 0. 02 (5) Chenic acid 0.02
(6) クェン酸ナトリウム 0. 1 (6) Sodium quenate 0.1
(7) グリセリン 1. 0 (7) Glycerin 1.0
(8) ヒドロキシェチルセルロース 0. 1 (8) Hydroxyethyl cellulose 0.1
(9) ゼンマイ科植物抽出物 (調製方法 3) 5. 0 製法:(1)に(2)及び (3)を溶解する。溶解後、(4)〜 (8)を順次添加した後、十分に 攪拌し、(9)を加え、均一に混合する。 (9) Windmill plant extract (Preparation method 3) 5.0 Production method: Dissolve (2) and (3) in (1). After dissolution, add (4) to (8) sequentially, then stir well, add (9), and mix uniformly.
[実施例 3]クリーム [Example 3] Cream
配合: Formula:
[表 C] [Table C]
( I ) スクヮラン 1 0. 0 (質量%) ( 2 ) ステアリン酸 2. 0 (I) Scullane 1 0.0 (mass%) (2) Stearic acid 2.0
(3) 水素添加パ一ム核油 0. 5 (3) Hydrogenated palm kernel oil 0.5
(4) 水素添加大豆リン脂質 0. 1 (4) Hydrogenated soybean phospholipid 0.1
(5) セ夕ノール 3. 6 (5) Seyu Nord 3.6
(6) 親油型モノステアリン酸グリセリン 2. 0 (6) Lipophilic glyceryl monostearate2.0
( 7 ) グリセリン 1 0. 0 (7) Glycerin 1 0. 0
(8) パラォキシ安息香酸メチル 0. 1 (8) Methyl paraoxybenzoate 0.1
(9) アルギニン (20質量%水溶液) 1 5. 0 (9) Arginine (20 mass% aqueous solution) 1 5. 0
(10) 精製水 1 0 0とする残部 (10) The balance of purified water 1 0 0
(II) カルボキシビ二ルポリマー ( 1質量%水溶液) 1 5. 0 (II) Carboxyvinyl polymer (1% by weight aqueous solution) 1 5. 0
(12) ゼンマイ科植物抽出物 (調製方法 1) 5. 0 製法:(1)〜(6)の油相成分を 80°Cにて加熱溶解する。一方(7)〜(10)の水相成分 を 80°Cにて加熱溶解する。これに前記油相成分を攪拌しながら加え、ホモジナイザ 一により均一に乳化する。乳化終了後、(11)を加え、冷却を開始し、 40°Cにて(12)
を加え、均一に混合する。 (12) Windmill plant extract (Preparation method 1) 5.0 Production method: Heat-dissolve the oil phase components of (1) to (6) at 80 ° C. On the other hand, the aqueous phase components (7) to (10) are heated and dissolved at 80 ° C. The oil phase component is added to this while stirring and uniformly emulsified with a homogenizer. After the emulsification, add (11) and start cooling at 40 ° C (12) And mix evenly.
[実施例 4]美容液 [Example 4] Cosmetic liquid
配合: Formula:
[表 D] [Table D]
( 1 ) 精製水 1 0 0とする残部(質量%)(1) The balance (mass%) of purified water 1 0 0
(2) グリセリン 0 (2) Glycerin 0
(3) ショ糖脂肪酸エステル 3 (3) Sucrose fatty acid ester 3
(4) カルボキシピ二ルポリマー ( 1質量%水溶液) 5 (4) Carboxypropyl polymer (1 mass% aqueous solution) 5
(5) アルギン酸ナトリウム(1質量%水溶液) 0 (5) Sodium alginate (1% by weight aqueous solution) 0
(6) モノラウリン酸ポリグリセリル 0 (6) Polyglyceryl monolaurate 0
(7) マカデミアナッツ油脂肪酸フィ トステリル 0 (7) Macadamia nut oil fatty acid phytosteryl 0
(8) N-ラウロイル -L-グルタミン酸ジ (フィ トステリル- 2一才クチルドデシル) (8) N-lauroyl-L-glutamate di (phytosteryl-2 1 year old cutyldecyl)
2 0 2 0
(9) 硬化パーム油 2 0 (9) Hardened palm oil 2 0
(10) スクヮラン (ォリーブ由来) 1 0 (10) Sukuran (Olive) 1 0
(11) ベへニルアルコール 0 (11) Behenyl alcohol 0
(12) ミツロウ 0 (12) Beeswax 0
(13) ホホパ油 1 0 (13) Jojoba oil 1 0
(14) 1、 3—ブチレングリコール 0 0 (14) 1, 3-Butylene glycol 0 0
(15) L—アルギニン ( 1 0質量%水溶液) 2 0 (15) L-Arginine (10% by mass aqueous solution) 2 0
(16) ゼンマイ科植物抽出物 (調製方法 2) 5 0 製法:(1)〜(6)の水相成分を混合し、 75°Cにて加熱溶解する。一方、(7)〜(14)の 油相成分を混合し、 75°Cにて加熱溶解する。次いで、上記水相成分に油相成分を 添加して予備乳化を行った後、ホモミキサーにて均一に乳化する。乳化終了後に冷 却を開始し、 50°Cにて(15)をカ卩える。さらに 40°Cまで冷却し、(16)を加え、均一に混 合する。 (16) Windmill plant extract (Preparation method 2) 50 Manufacturing method: Mix the aqueous phase components (1) to (6) and dissolve at 75 ° C with heating. On the other hand, the oil phase components (7) to (14) are mixed and dissolved by heating at 75 ° C. Next, the oil phase component is added to the aqueous phase component and preliminary emulsification is performed, followed by uniform emulsification with a homomixer. Start cooling after emulsification and cover (15) at 50 ° C. Cool to 40 ° C, add (16), and mix evenly.
[実施例 5]水性ジ ル [Example 5] Aqueous gel
配合: Formula:
[表 E]
( 1 ) 力ルポキシビ二ルポリマ一 0. 5 (質量%)[Table E] (1) Forced L-Poxyvinyl Polymer 0.5 (mass%)
(2) 精製水 1 00とする残部 (2) The balance of 100 purified water
(3) 水酸化ナトリウム (1 0質量%水溶液) 0. 5 (3) Sodium hydroxide (10 mass% aqueous solution) 0.5
(4) エタノール 1 0. 0 (4) Ethanol 1 0. 0
(5) パラォキシ安息香酸メチル 0. 1 (5) Methyl paraoxybenzoate 0.1
(6) 香料 0. 1 (6) Fragrance 0. 1
(7) ゼンマイ科植物抽出物 (調製方法 2) 3. 0 (7) Windmill plant extract (Preparation method 2) 3.0
(8) ポリオキシエチレン (60 E. O. ) 硬化ヒマシ油 1. 0 製法:(1)を (2)に加え、均一に攪拌した後、(3)を加える。均一に攪拌した後、(4) に予め溶解させた(5)を加える。均一に攪拌した後、予め混合しておいた(6)〜(8) を加え、均一に攪拌混合する。 (8) Polyoxyethylene (60 E. O.) hydrogenated castor oil 1.0 Manufacturing method: Add (1) to (2), stir uniformly, and then add (3). After stirring uniformly, add (5) previously dissolved in (4). After stirring uniformly, add (6) to (8) previously mixed and stir and mix uniformly.
[実施例 6]クレンジング料 [Example 6] Cleansing fee
配合: Formula:
[表 F] [Table F]
( 1 ) スクヮラン 8 1. 0 (質量%)(1) Screen 8 1 0 (mass%)
(2) イソステアリン酸: 1 5. 0 (2) Isostearic acid: 1 5. 0
(3) 精製水 1 00とする残部 (3) The balance of 100 purified water
(4) ゼンマイ科植物抽出物 (調製方法 3) 4. 0 製法:(1)と(2)を均一に溶解する。これに、(3)と (4)を順次加え、均一に混合する。 (4) Windmill plant extract (Preparation method 3) 4.0 Production method: Dissolve (1) and (2) uniformly. Add (3) and (4) to this, and mix evenly.
[実施例 7]洗顔フォーム [Example 7] Face washing foam
配合: Formula:
[表 G] [Table G]
( 1 ) ステアリン酸 1 6. 0 (質量%)(1) Stearic acid 16.0 (mass%)
(2) ミリスチン酸 1 6. 0 (2) Myristic acid 1 6. 0
(3) 親油型モノステアリン酸グリセリン 2. 0 (3) Lipophilic glyceryl monostearate2.0
(4) グリセリン 2 5. 0 (4) Glycerin 2 5. 0
(5) 水酸化ナトリウム 7. 5 (5) Sodium hydroxide 7.5
(6) ヤシ油脂肪酸アミ ドプロピルべタイン 1. 0 (6) Palm oil fatty acid amidpropyl betaine 1.0
(7) 精製水 1 00とする残部 (7) The balance of 100 purified water
(8) ゼンマイ科植物抽出物 (調製方法 3) 5. 0 製法:(1)〜(4)の油相成分を 80°Cにて加熱溶解する。一方(5)〜(7)の水相成分 を 80°Cにて加熱溶解し、油相成分と均一に混合撹拌する。冷却を開始し、 40°Cにて
(8)を加え、均一に混合する。 (8) Windmill plant extract (Preparation method 3) 5.0 Production method: The oil phase components (1) to (4) are heated and dissolved at 80 ° C. On the other hand, the water phase components (5) to (7) are heated and dissolved at 80 ° C, and the oil phase components are mixed and stirred uniformly. Start cooling at 40 ° C Add (8) and mix evenly.
[実施例 8]メイクアップべ一」 [Example 8] Make-up base "
配合: Formula:
[表 H] [Table H]
( I ) スクヮラン 1 0. 2 (質量%) ( 2 ) セタノール 2. 0 (I) squalene 1 0.2 (mass%) (2) cetanol 2.0
(3) グリセリントリー 2—ェチルへキサン酸エステル 2. 5 (3) Glycerol tree 2-ethylhexanoate 2.5
(4) 親油型モノステアリン酸グリセリル 1. 0 (4) Lipophilic glyceryl monostearate1.0
( 5 ) プロピレングリコール 1 1. 0 (5) Propylene glycol 1 1. 0
(6) ショ糖脂肪酸エステル 1. 3 (6) Sucrose fatty acid ester 1.3
(7) 精製水 1 00とする残部 (7) The balance of 100 purified water
(8) 酸化チタン 1. 0 (8) Titanium oxide 1.0
(9) ベンガラ 0. 1 (9) Bengala 0.1
(10) 黄酸化鉄 0. 4 (10) Yellow iron oxide 0.4
(II) 香料 0. 1 (II) Fragrance 0. 1
(12) ゼンマイ科植物抽出物 (調製方法 2) 3. 0 製法:(1)〜(4)の油相成分を混合し、 75°Cにて加熱溶解する。一方、(5)〜(7)の 水相成分を混合し、 75°Cにて加熱溶解し、これに(8)〜(10)の顔料をカ卩え、ホモミキ サ一にて均一に分散させる。この水相成分に前記油相成分を加え、ホモミキサーに て乳化する。乳化終了後に冷却を開始し、 40°Cにて(11)と(12)の成分を加え、均一 に混合する。 (12) Windmill plant extract (Preparation method 2) 3.0 Manufacturing method: Mix the oil phase components of (1) to (4), and dissolve by heating at 75 ° C. On the other hand, the aqueous phase components (5) to (7) are mixed and dissolved by heating at 75 ° C. The pigments (8) to (10) are added to this and uniformly dispersed with a homomixer. Let The oil phase component is added to the water phase component and emulsified with a homomixer. Start cooling after emulsification, add ingredients (11) and (12) at 40 ° C and mix evenly.
[実施例 9]乳液状ファンデーション [Example 9] Emulsion foundation
配合: Formula:
[表 I]
[Table I]
( I ) メチルポリシロキサン 2. 0 (質量%) (2 ) スクヮラン 5. 0 (I) Methylpolysiloxane 2.0 (mass%) (2) Scullane 5.0
(3) ミリスチン酸ォクチルドデシル 5. 0 (3) Octyldodecyl myristate 5.0
(4) セ夕ノール 1. 0 (4) Seyu Nord 1. 0
(5) ポリオキシエチレン(2 0 E. 〇. )ソルビタンモノステアリン酸エステル (5) Polyoxyethylene (20 E. 〇.) Sorbitan monostearate
1. 3 13
(6) モノステアリン酸ソルビタン 0. 7 (6) Sorbitan monostearate 0.7
(7) 1、 3—ブチレングリコ一ル 8. 0 (7) 1,3-Butylene glycol 8.0
(8) キサンタンガム 0. 1 (8) Xanthan gum 0.1
(9) パラォキシ安息香酸メチル 0. 1 (9) Methyl paraoxybenzoate 0.1
(10) 精製水 1 0 0とする残部 (10) The balance of purified water 1 0 0
(II) 酸化チタン 9. 0 (II) Titanium oxide 9.0
(12) タルク 7. 4 (12) Talc 7.4
(13) ベンガラ 0. 5 (13) Bengala 0.5
(14) 黄酸化鉄 1. 1 (14) Yellow iron oxide 1.1
(15) 黒酸化鉄 0. 1 (15) Black iron oxide 0.1
(16) 香料 0. 1 (16) Fragrance 0. 1
(17) ゼンマイ科植物抽出物 (調製方法 1 ) 4. 0 製法:(1)〜(6)の油相成分を混合し、 75°Cにて加熱溶解する。一方、(7)〜(10)の 水相成分を混合し、 75°Cにて加熱溶解し、これに(11)〜(15)の顔料をカ卩え、ホモミ キサ一にて均一に分散する。油相成分を加え、乳化を行う。乳化終了後に冷却を開 始し、 40°Cにて(16)と(17)の成分を順次カ卩え、均一に混合する。 (17) Windmill plant extract (Preparation method 1) 4.0 Production method: Mix the oil phase components (1) to (6) and dissolve at 75 ° C with heating. On the other hand, the water phase components (7) to (10) are mixed and dissolved by heating at 75 ° C. The pigments (11) to (15) are added to this and uniformly dispersed with a homomixer. To do. Add oil phase ingredients and emulsify. Cooling is started after emulsification, and components (16) and (17) are sequentially added at 40 ° C and mixed uniformly.
[実施例 10]油中水型ェモリエントクリーム [Example 10] Water-in-oil emollient cream
配合: Formula:
[表 J] [Table J]
( 1 ) 流動パラフィン 34. 0 (質量%)(1) Liquid paraffin 34.0 (mass%)
(2) マイクロクリスタリンワックス 2. 0 (2) Microcrystalline wax 2.0
(3) ワセリン 5. 0 (3) Vaseline 5.0
(4) ジグリセリンォレイン酸エステル 5. 0 (4) Diglycerinoleate 5.0
(5) 塩化ナトリウム 3 (5) Sodium chloride 3
(6) 塩化カリウム 0. 1 (6) Potassium chloride 0.1
(7) プロピレンダリコール 3. 0 (7) Propylene Daricol 3.0
(8) 1、 3—ブチレングリコール 5. 0 (8) 1, 3-butylene glycol 5.0
(9) パラォキシ安息香酸メチル 0. (9) Methyl paraoxybenzoate 0.
(10) ゼンマイ科植物抽出物 (調製方法 1) 3. 0 (10) Windmill plant extract (Preparation method 1) 3.0
(11) 精製水 1 00とする残部 (11) The balance of 100 purified water
(12) 香料 0. 1
製法:(5)と(6)を(11)の一部に溶解して 50°Cとし、 50°Cに加熱した (4)に撹拌しな 力 Sら徐々に加える。これを混合した後、 70°Cにて加熱溶解した(1)〜(3)に均一に分 散する。これに、(7)〜(10)を(11)の残部に 70°Cにて加熱溶解したものを撹拌しな がらカ卩え、ホモミキサーにて乳化する。乳化終了後に冷却を開始し、 40°Cにて(12) を加え、均一に混合する。 (12) Fragrance 0. 1 Manufacturing method: Dissolve (5) and (6) in a part of (11) to 50 ° C, and heat to 50 ° C (4). After mixing this, disperse uniformly into (1) to (3), which is heated and dissolved at 70 ° C. Add (7) to (10) to the remainder of (11) by heating and dissolving at 70 ° C while stirring and emulsify with a homomixer. Start cooling after emulsification, add (12) at 40 ° C, and mix uniformly.
[0061] [実施例 11]パック [0061] [Example 11] Pack
配合: Formula:
[表 K] [Table K]
(1) 精製水 1 00とする残部(質量%)(1) The balance (mass%) of purified water 100
(2) ポリビニルアルコール 12. 0 (2) Polyvinyl alcohol 12.0
(3) エタノール 1 7. 0 (3) Ethanol 1 7.0
(4) グリセリン 9. 0 (4) Glycerin 9.0
(5) ポリエチレングリコール (平均分子量 1 000) 2. 0 (5) Polyethylene glycol (average molecular weight 1 000) 2.0
(6) ゼンマイ科植物抽出物 (調製方法 2) 5. 0 (6) Windmill plant extract (Preparation method 2) 5.0
(7) 香料 0. 1 製法:(2)と(3)を混合し、 80°Cに加温した後、 80°Cに加温した(1)に溶解する。均 一に溶解した後、(4)と(5)を加え、攪拌しながら冷却を開始する。 40°Cまで冷却し、 (6)と(7)を加え、均一に混合する。 (7) Fragrance 0.1 Production method: (2) and (3) are mixed, heated to 80 ° C, and then dissolved in (1) heated to 80 ° C. After evenly dissolving, add (4) and (5) and start cooling with stirring. Cool to 40 ° C, add (6) and (7), and mix evenly.
[実施例 12]入浴剤 [Example 12] Bath salt
配合: Formula:
[表し] [Representation]
(1 ) 香料 0. 3 (質量%)(1) Fragrance 0.3 (mass%)
(2) ゼンマイ科植物抽出物 (調製方法 3) 3. 0(2) Windmill plant extract (Preparation method 3) 3.0
(3) 炭酸水素ナトリゥム 5 0. 0 (3) Sodium hydrogen carbonate 5 0. 0
(4) 硫酸ナトリウム 46. 7 製法:(1)〜(4)を均一に混合する。 (4) Sodium sulfate 46.7 Production method: Mix (1) to (4) uniformly.
[0063] [実施例 13]ヘアーワックス [0063] [Example 13] Hair wax
配合: Formula:
[表 M]
( 1 ) ステアリン酸 3. 0 (質量%)[Table M] (1) Stearic acid 3.0 (mass%)
(2) マイクロクリスタリンワックス 2. 0(2) Microcrystalline wax 2.0
(3) セチルアルコール 3. 0(3) Cetyl alcohol 3.0
(4) 高重合メチルポリシロキサン 2. 0(4) Highly polymerized methylpolysiloxane 2.0
(5) メチルポリシロキサン 5. 0(5) Methylpolysiloxane 5.0
(6) ポリ (ォキシエチレン ·ォキシプロピレン) メチルポリシロキサン共重合体 (6) Poly (oxyethylene / oxypropylene) methylpolysiloxane copolymer
1. 0 Ten
(7) パラォキシ安息香酸メチル 0. 1 (7) Methyl paraoxybenzoate 0.1
(8) 1、 3—ブチレングリコール 7 - 5(8) 1, 3-butylene glycol 7-5
(9) アルギニン 0. 7(9) Arginine 0.7
(10) 精製水 1 00とする残部(10) The balance of 100 purified water
(11) ゼンマイ科植物抽出物 (調製方法 3) 4. 0(11) Windmill plant extract (Preparation method 3) 4.0
(12) 香料 0. 1 製法:(1)〜(6)の油相成分を混合し、 75°Cにて加熱溶解後する。一方、(7)〜(10) の水相成分を 75°Cにて加熱溶解し、前記油相成分を加え、ホモミキサーにて乳化す る。乳化終了後に冷却を開始し、 40°Cにて(11)と(12)の成分を加え、均一に混合す る。 (12) Fragrance 0.1 Production method: Mix the oil phase components (1) to (6), and heat and dissolve at 75 ° C. On the other hand, the aqueous phase components (7) to (10) are dissolved by heating at 75 ° C, and the oil phase component is added and emulsified with a homomixer. Start cooling after emulsification, add ingredients (11) and (12) at 40 ° C, and mix uniformly.
[0064] [実施例 14]ヘアートニック [0064] [Example 14] Hair art nick
配合: Formula:
[表 N] [Table N]
( 1 ) エタノール 50. 0 (質量%)(1) Ethanol 50.0 (mass%)
(2) 精製水 100とする残部(2) The balance of 100 purified water
(3) ゼンマイ科植物抽出物 (調製方法 1) 3. 0(3) Windmill plant extract (Preparation method 1) 3.0
(4) 香料 0. 1 製法:(1)〜(4)の成分を混合、均一化する。 (4) Fragrance 0.1 Production method: Mix and homogenize components (1) to (4).
[0065] <保湿作用の評価 1 (保湿性) > [0065] <Evaluation of moisturizing action 1 (humidity retention)>
実施例 3の皮膚外用剤を用いた使用試験を行い、ゼンマイ科植物抽出物の保 湿性について評価した。その際、実施例 1において配合したゼンマイ科植物抽出物 を、 50%質量エタノール水溶液に代えたものを比較例 1、実施例 3において配合した ゼンマイ科植物抽出物を、 50%質量エタノール水溶液に代えたものを比較例 2とし て、同様に使用試験を行った。 A use test using the external preparation for skin of Example 3 was carried out, and the moisturizing property of the spring plant extract was evaluated. At that time, the genus plant extract formulated in Example 1 was replaced with a 50% mass ethanol aqueous solution, and the genus plant extract formulated in Comparative Example 1 and Example 3 was replaced with a 50% mass ethanol aqueous solution. A test was conducted in the same manner as Comparative Example 2 using the sample.
[0066] 男女パネラー 15名を一群として、 4群のパネラーに各試料をブラインドにてそれぞ
れ 1か月間使用させ、「感じる」、「どちらともいえない」、「感じない」の三段階で評価し た。表 9に、各評価を得たパネラー数を示す。 [0066] A group of 15 male and female panelists, and each sample was blinded to 4 groups of panelists. It was used for a month, and was evaluated in three stages: “feel”, “can't say”, or “do not feel”. Table 9 shows the number of panelists that obtained each evaluation.
[表 9] [Table 9]
[0068] 表 9より、ゼンマイ科植物抽出物を配合した実施例使用群においては、 80%以上 のパネラーに明確な保湿性が感じられることがわ力つた。このことから、ゼンマイ科植 物抽出物は、優れた保湿作用を有することが明らかとなった。 [0068] From Table 9, it was found that 80% or more of panelists could feel clear moisturizing property in the use group of the examples in which the extract of the spring family plant was blended. From this, it has been clarified that the spring-like plant extract has an excellent moisturizing action.
[0069] <保湿作用の評価 2 (肌荒れ、肌のキメ、肌の透明感) > [0069] <Evaluation of moisturizing effect 2 (rough skin, skin texture, skin transparency)>
実施例 3及び比較例 1、 2の皮膚外用剤を用いた使用試験を行い、肌荒れ、肌 のキメ、肌の透明感について、それらの症状の改善効果を評価した。 A use test using the external preparation for skin of Example 3 and Comparative Examples 1 and 2 was performed, and the improvement effect of these symptoms was evaluated with respect to rough skin, skin texture and skin transparency.
[0070] 各試料につ 、て、肌荒れ、肌のキメ、肌の透明感につ!/、て悩みを持つ 20〜50才 代の男女パネラー 20名を一群とし、 4群のパネラーに各試料をブラインドにてそれぞ れ 1か月間使用させ、使用前後の皮膚状態の変化を観察して評価した。皮膚状態の 指標として、肌荒れ、肌のキメ、肌の透明感について、「改善」、「やや改善」、「変化 なし」の三段階で評価した。肌荒れと肌の透明感は目視にて評価し、肌のキメはマイ クロスコープを用いて観察した。表 10に各評価を得たパネラー数を示す。 [0070] Each sample has rough skin, smooth skin, and clear skin! / A group of 20 to 50-year-old male and female panelists who have troubles. Each was used for 1 month with blinds, and changes in skin condition before and after use were observed and evaluated. As indicators of skin condition, rough skin, skin texture and skin transparency were evaluated in three stages: “Improved”, “Slightly improved” and “No change”. The rough skin and the transparency of the skin were evaluated visually, and the texture of the skin was observed using a microscope. Table 10 shows the number of panelists that obtained each evaluation.
[0071] [表 10] 項目 評価 実施例 1 実施例 3 比較例 1 比較例 2 [0071] [Table 10] Item Evaluation Example 1 Example 3 Comparative Example 1 Comparative Example 2
改善 16 15 3 2 Improvement 16 15 3 2
肌荒れ やや改善 3 4 5 4 Rough skin slightly improved 3 4 5 4
変化なし 1 1 12 14 No change 1 1 12 14
改善 15 15 4 4 Improvement 15 15 4 4
肌のキメ やや改善 2 4 5 4 Slight texture improvement 2 4 5 4
変化なし 3 1 1 1 12 No change 3 1 1 1 12
改善 16 16 5 4 Improvement 16 16 5 4
透明感 やや改善 3 2 4 5 Transparency Slightly improved 3 2 4 5
変化なし 1 2 1 1 1 1
表 10より、肌荒れ、肌のキメ、肌の透明感について、ゼンマイ科植物抽出物を含有 しない比較例 1、 2使用群においては、半数以上のパネラーに改善が認められなかつ たが、ゼンマイ科植物抽出物を配合した実施例使用群おいては、 70%以上のパネラ 一に明確な改善が認められた。このことから、ゼンマイ科植物抽出物は、肌荒れ、肌 のキメ、肌の透明感において、皮膚症状の改善に優れた効果を有することがわかつ た。 No change 1 2 1 1 1 1 From Table 10, it was found that more than half of the panelists did not show improvement in rough skin, skin texture, and skin transparency in comparative examples 1 and 2 that did not contain the extract of the springfish plant. In the example use group containing the extract, a clear improvement was observed in more than 70% of the panelists. From this, it has been found that the spring-like plant extract has an excellent effect on improving skin symptoms in terms of rough skin, skin texture, and skin transparency.
以上のことから、ゼンマイ科植物抽出物は優れた保湿作用を有することが明らかと なった。
From the above, it has been clarified that the spring plant extract has an excellent moisturizing action.
Claims
[1] ゼンマイ科 (Osmundaceae)植物より選ばれる 1種または 2種以上の植物またはそ の抽出物を有効成分とする保湿剤。 [1] A moisturizer comprising as an active ingredient one or more plants selected from Osmundaceae plants or extracts thereof.
[2] ゼンマイ科 (Osmundaceae)植物より選ばれる 1種または 2種以上の植物またはそ の抽出物を有効成分とする細胞賦活剤。 [2] A cell activator comprising, as an active ingredient, one or more plants selected from Osmundaceae plants or extracts thereof.
[3] ゼンマイ科 (Osmundaceae)槭物より撰ばれる 1種または 2種以 トの槠物ま は の抽出物を有効成分とする美白剤。 [3] A whitening agent containing as an active ingredient one or two or more extracts from Osmundaceae.
[4] ゼンマイ科 (Q^mundae^)植物より選ばれる 1種または 2種以上の植物またはそ の抽出物を有効成分とする中性脂肪蓄積抑制剤。 [4] Neutral fat accumulation inhibitor containing one or more plants selected from the spring power family (Q ^ mundae ^) or an extract thereof as an active ingredient.
[5] ゼンマイ科 (Osmundaceae)槭物より撰ばれる 1種または 2種以 hの槠物ま は の抽出物を有効成分とする抗酸化剤。 [5] Antioxidants containing as an active ingredient an extract of one or two or more kinds of pork from Osmundaceae.
[6] ゼンマイ科 (Qmimdas^)植物より選ばれる 1種または 2種以上の植物またはそ の抽出物を含有することを特徴とする皮膚外用剤。
[6] A topical skin preparation characterized by containing one or more plants selected from the family Qmimdas ^ or an extract thereof.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2006/315808 WO2008018133A1 (en) | 2006-08-10 | 2006-08-10 | Moisturizing agent, cell-activating agent, skin-whitening agent, agent for suppressing triglyceride accumulation, antioxidant and external preparation for skin |
JP2008528684A JPWO2008018133A1 (en) | 2006-08-10 | 2006-08-10 | Moisturizer, cell activator, whitening agent, neutral fat accumulation inhibitor, antioxidant, and external preparation for skin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2006/315808 WO2008018133A1 (en) | 2006-08-10 | 2006-08-10 | Moisturizing agent, cell-activating agent, skin-whitening agent, agent for suppressing triglyceride accumulation, antioxidant and external preparation for skin |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008018133A1 true WO2008018133A1 (en) | 2008-02-14 |
Family
ID=39032679
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/315808 WO2008018133A1 (en) | 2006-08-10 | 2006-08-10 | Moisturizing agent, cell-activating agent, skin-whitening agent, agent for suppressing triglyceride accumulation, antioxidant and external preparation for skin |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2008018133A1 (en) |
WO (1) | WO2008018133A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102021124078A1 (en) | 2021-09-17 | 2023-03-23 | Timm Golüke | Cosmetic composition for application to the skin |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03218466A (en) * | 1989-02-06 | 1991-09-26 | Chiba Seifun Kk | Plant glycolipid positive in limulus test, immune function activator, immune function activator for animal, immune function inspecting drug, immune function inspecting drug for animal, non-pharmaceuticals, cosmetics, food, functional food, drinks, feed containing such glycolypid |
JPH0449244A (en) * | 1990-06-15 | 1992-02-18 | Chiba Seifun Kk | Antidiabetic agent and antidiabetic agent for animal |
JPH06340532A (en) * | 1993-06-01 | 1994-12-13 | Nippon Beet Sugar Mfg Co Ltd | Suppressing agent against increase of blood lipid or lowering agent against the same |
US20040126344A1 (en) * | 2002-12-26 | 2004-07-01 | Avon Products, Inc. | Compositions having glycolipid to lighten skin and alter post-inflammatory hyperpigmentation |
JP2006508171A (en) * | 2002-12-26 | 2006-03-09 | エイボン プロダクツ インコーポレーテッド | Topical compositions containing natural ingredients and methods of use |
JP2006514997A (en) * | 2003-05-12 | 2006-05-18 | エイボン プロダクツ インコーポレーテッド | Cosmetic composition for improving aesthetic appearance of skin and method of using the same |
-
2006
- 2006-08-10 WO PCT/JP2006/315808 patent/WO2008018133A1/en active Application Filing
- 2006-08-10 JP JP2008528684A patent/JPWO2008018133A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03218466A (en) * | 1989-02-06 | 1991-09-26 | Chiba Seifun Kk | Plant glycolipid positive in limulus test, immune function activator, immune function activator for animal, immune function inspecting drug, immune function inspecting drug for animal, non-pharmaceuticals, cosmetics, food, functional food, drinks, feed containing such glycolypid |
JPH0449244A (en) * | 1990-06-15 | 1992-02-18 | Chiba Seifun Kk | Antidiabetic agent and antidiabetic agent for animal |
JPH06340532A (en) * | 1993-06-01 | 1994-12-13 | Nippon Beet Sugar Mfg Co Ltd | Suppressing agent against increase of blood lipid or lowering agent against the same |
US20040126344A1 (en) * | 2002-12-26 | 2004-07-01 | Avon Products, Inc. | Compositions having glycolipid to lighten skin and alter post-inflammatory hyperpigmentation |
JP2006508171A (en) * | 2002-12-26 | 2006-03-09 | エイボン プロダクツ インコーポレーテッド | Topical compositions containing natural ingredients and methods of use |
JP2006514997A (en) * | 2003-05-12 | 2006-05-18 | エイボン プロダクツ インコーポレーテッド | Cosmetic composition for improving aesthetic appearance of skin and method of using the same |
Non-Patent Citations (1)
Title |
---|
HAYASHI M. ET AL.: "Noto no Sansai o Katsuyo shita Tokusanhin Kaihatsu II Sansai no Kinosei no Kensaku (Studies on the development of the principal products maked from edible wild plants cultivated in the northern area of Ishikawa prefecture)", BULLETIN OF THE ISHIKAWA AGRICULTURE RESEARCH CENTER, no. 24, 2002, pages 61 - 64, XP003021027 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102021124078A1 (en) | 2021-09-17 | 2023-03-23 | Timm Golüke | Cosmetic composition for application to the skin |
WO2023041411A1 (en) * | 2021-09-17 | 2023-03-23 | Golueke Timm | Cosmetic composition for use on the skin |
Also Published As
Publication number | Publication date |
---|---|
JPWO2008018133A1 (en) | 2009-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5557414B2 (en) | Moisturizer, cell activator, and whitening agent | |
JP2008063266A (en) | Anti-aging agent, bleaching agent, anti-oxidizing agent and anti-inflammatory agent | |
JP2010070501A (en) | Moisturizer, anti-aging agent, antioxidant, neutral fat-accumulation inhibitor, skin-beautifying agent, antiinflammatory agent, skin preparation for external use and peroral preparation | |
JP5117092B2 (en) | Moisturizer, anti-aging agent, whitening agent, antioxidant, slimming agent, treatment agent, arginase activity promoter and external preparation for skin | |
JP5014343B2 (en) | Nemagaridake-containing composition, moisturizer, cell activator, whitening agent and antioxidant | |
JP5312731B2 (en) | Topical skin preparation | |
JP4689215B2 (en) | Moisturizer, cell activator, whitening agent, and collagenase inhibitor | |
JP2007277100A (en) | Humectant, cell activator, dermal fibroblast activator, epidermal cell activator, collagen production accelerator, antioxidant, anti-aging agent, beautifully whitening agent or melanin production inhibitor | |
JP5247548B2 (en) | Moisturizer, anti-aging agent, neutral fat accumulation inhibitor, whitening agent, anti-inflammatory agent, topical skin preparation, oral preparation | |
JP5465037B2 (en) | Anti-aging agent, antioxidant, whitening agent, immunostimulant, external preparation for skin and functional oral composition | |
WO2008018133A1 (en) | Moisturizing agent, cell-activating agent, skin-whitening agent, agent for suppressing triglyceride accumulation, antioxidant and external preparation for skin | |
JP5025201B2 (en) | Moisturizer, anti-aging agent, whitening agent, anti-inflammatory agent, and antioxidant | |
JP4748962B2 (en) | Moisturizer, cell activator, whitening agent, and antioxidant | |
JP4970442B2 (en) | Whitening agent | |
JP4050727B2 (en) | Moisturizer, cell activator, whitening agent, antioxidant, and skin external preparation | |
JP5388555B2 (en) | Moisturizer, anti-aging agent, antioxidant, slimming agent, whitening agent, anti-inflammatory agent, immunostimulant, external preparation for skin, functional oral composition | |
JP4931452B2 (en) | Moisturizer, cell activator, whitening agent, and antioxidant | |
JP4994684B2 (en) | Moisturizer, cell activator, and antioxidant | |
JP2008231016A (en) | External preparation for skin, humectant, anti-ageing agent, antioxidant, anti-inflammatory agent, bleaching agent, and slimming agent | |
JP4291647B2 (en) | Cell activator, whitening agent, collagen production promoter, antioxidant, and skin external preparation | |
JP5313003B2 (en) | Moisturizer | |
JP5265489B2 (en) | Moisturizer, anti-aging agent, antioxidant, whitening agent, anti-inflammatory agent, immunostimulant, topical skin preparation, oral preparation | |
JP4869638B2 (en) | Cell activator, whitening agent, antioxidant, amylase inhibitor, and humectant | |
JP5009544B2 (en) | Moisturizer, cell activator, antioxidant, and collagenase inhibitor | |
JP5013726B2 (en) | Moisturizer, cell activator, antioxidant, and collagenase inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06782612 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008528684 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06782612 Country of ref document: EP Kind code of ref document: A1 |